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ABSTRACT 
The WHO has listed the development of single dose vaccines as one of the "grand 
challenges" for human health. Traditional vaccination regimes require 3 to 4 doses of an 
antigen to induce lasting immunity. This study focused on the development of a single dose 
vaccine based on biodegradable polyanhydrides. Tetanus toxoid (TT) was used as a model 
antigen. The microspheres evaluated were copolymers of sebacic acid and 1,6-bis(p-
carboxyphenoxy)hexane. By changing copolymer ratios, release kinetics of the antigen were 
modulated to obtain a sustained release, mimicking multiple doses of traditional vaccine. 
Mice (C3H/HeOuJ) were immunized once with different vaccine formulations of 
polyanhydride microspheres containing TT. Serum antibody titers to TT were evaluated over 
the course of 28 weeks. Following immunization with the TT-loaded microspheres, resultant 
antibody titers and avidity were comparable in magnitude and duration to that obtained in 
mice receiving an equivalent single dose of TT (3-10 µg). The results indicate that the 
efficacy of the immunization regimen and modulation of the immune response (i.e., Thl 
shift) improved by the addition of a small amount of soluble (i.e., non-encapsulated) TT (0.5 
µg) along with the TT-loaded microspheres. Incorporation of 0.5 µg of TT along with TT-
loaded microspheres in the vaccine induced a shift in the antibody isotype as demonstrated 
by decreased production of IgG 1. Evidence based on antibody and recall proliferation 
responses show that polyanhydride microspheres can be used as an effective single dose 
vaccine delivery system. 
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CHAPTER 1: 
GENERAL INTRODUCTION AND LITERATURE REVIEW 
General Introduction 
Vaccination against infectious agents has greatly improved the health of both humans 
and livestock species worldwide. Despite vast improvements in vaccination over the past 
several decades, infectious disease still remains the largest cause of death world-wide; 
unfortunately, many of these deaths occur in children and infants caused by diseases that are 
preventable by vaccination [1,2]. Most vaccines require the administration of multiple doses 
within specific windows of time to create lasting, protective immunity. For example, the 
current recommendation for humans is four doses of diphtheria toxoid, tetanus toxoid (TT), 
and pertussis combined vaccine given at 2, 4, 6, and 18 months of age with a booster every 
ten years [3-5]. Health care workers have observed that dropout rate in a vaccination 
programs can reach as high as 70% in some developing countries due to voluntary and 
involuntary reasons. Furthermore, the costs associated with the vaccine delivery can account 
for 80% of the cost of immunization programs (i.e., personnel time, refrigeration equipment, 
new needles) [6]. A single dose vaccine, whether for humans or animals, would greatly 
increase patient compliance, increase efficacy of many vaccines (i.e., a full dosing regimen 
received at once), and reduce the costs associated with vaccination programs. The World 
Health Organization (WHO) listed the development of a single dose vaccine as number one 
in their "Grand Challenges" for human health. 
There are an increasing number of peptide subunit and recombinant protein vaccines 
being developed which lack stimulatory bacterial components (i.e. adjuvants) and, because of 
this omission, fail to effectively induce protective immunity. Adjuvants, by definition, serve 
three functions: first, to slow the dispersion of the antigen and prevent quick clearance of the 
antigen from the body; second, to target the antigen to the antigen presenting cells of the 
immune system; and third, to enhance the immune response by stimulating the innate 
immune system. Many adjuvants used experimentally are components of bacterial pathogens 
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or other compounds that contain repeated motifs or patterns recognized by receptors on host 
cells (e.g., toll-like receptors). Many of these components are too toxic or produce 
undesirable side effects limiting their usefulness in vaccination regimen for both animals and 
man. In the United States, two adjuvants are currently approved for use in humans in the 
United States, and these are alum and MF59, a biodegradable plant oil emulsion containing 
muramyl tripeptide [7]. Highly purified muramyl tripeptide (MTP) is a synthetic component 
similar to that found in mycobacterial cell walls and MTP retains immunostimulatory 
properties while eliminating much the toxic effects associated with the whole bacterium [8]. 
Alum is a general term for any adjuvant based upon the use of aluminum hydroxide, 
aluminum phosphate, or similar aluminum salt. Alum is generally suspended in a gel-like 
matrix into which the immunogen is emulsified [9]. A majority of human vaccines use alum 
as an adjuvant, and one of the drawbacks associated with the use of alum is that it cannot be 
frozen or lyophilized [4]. Alum has been occasionally associated with severe local reactions, 
including the development of granulomas [ 10, 11]. Both adjuvants approved for human 
vaccines induce elevated antibody titers and dominant Th2-type immune responses but are 
deficient in inducing cell-mediated immune responses [12]. Alum has been implicated in 
contributing to the rise in childhood allergies because of the potent Th2-type response that is 
induced [13,14]. An immune response of the Th2-type is characterized by the production of 
IL-4, IL-5, IL-10 and IL-13 producing elevated IgGl and IgE antibody isotypes. Thl-type 
responses are characterized by the production ofIFN-y and TNF-13 and is associated with 
cell-mediated immunity including activated macrophages and delayed-type hypersensitivity 
[15]. Immune responses of the Thl type are directed more towards intracellular pathogens 
and are necessary for clearance of many viruses and some bacteria (e.g. Mycobacterium 
tuberculosis) [12]. Thus, there is also a need to develop new safe adjuvants that will induce 
protective immunity following a single vaccination as well as enhance Thl-type immunity. 
Biodegradable polymers have been studied for many years because they show 
promise for the development of single dose vaccines [ 16, 17]. Microspheres consisting of 
polyesters have been the most widely studied. Polymers of lactic acid and glycolic acid (e.g. 
poly(lactide-co-glycolide)) have been utilized in biomedical applications such as bone pins 
and dissolvable sutures for many years and recently have proven effective as vaccine 
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delivery vehicles for the induction of protective immunity laboratory animals [18,19). 
Because polyesters are relatively hydrophilic, they degrade by a mechanism referred to as 
bulk erosion. Bulk erosion is where the polymer degrades simultaneously from both the 
exterior and interior surfaces because of the porosity of the material [21]. Briefly, water 
diffuses into the polymer creating a swollen matrix from which the encapsulated antigen is 
released by diffusion [20). As the polyester degrades and the acidic monomers are released, 
an acidic microenvironment is created. Prolonged exposure to aqueous or acidic 
environments has been shown to be detrimental to the stability and immunogenicity of 
proteins, especially the proteins used in recombinant and subunit vaccines, e.g., tetanus 
toxoid (TT) and diphtheria toxoid [21,22]. While polyesters may have immunostimulatory 
properties, true adjuvanticity (i.e., immunomodulation) beyond a simple depot effect has not 
been evaluated [23]. 
Another class of biodegradable materials with controlled release characteristics 
similar to polyesters are made from anhydride monomers. Polyanhydrides can also be 
fabricated into protein-loaded microspheres and are currently approved by the FDA for use in 
a variety of biomedical applications [24]. Polyanhydrides are more hydrophobic than 
polyesters and, therefore, degrade by surface erosion rather than by bulk erosion [25,26). The 
hydrophobicity of polyanhydrides prevents water from penetrating to the interior of the 
microsphere thus preserving the encapsulated antigen in its native state (i.e., increased 
stability) until that layer of the microsphere is degraded. Furthermore, the degradation 
products of polyanhydrides are less acidic than those of polyesters, which may further 
enhance the stability of encapsulated antigens and reduce tissue reactions to the polymer. 
Despite these beneficial characteristics, the use of polyanhydrides for vaccine delivery has 
not been evaluated. 
One of the objectives of this project was to evaluate the utility of biodegradable 
microspheres formulated from CPH:SA copolymers as vaccine carriers. The model antigen 
chosen for these studies was tetanus toxoid (TT), a large protein (150 kDa) that contains 
multiple immunogenic epitopes [2]. Microspheres containing TT were formulated using 
different ratios of CPH to SA (e.g. 20:80 and 50:50 copolymers) that exhibited different 
release kinetics in vitro. C3H strain mice were immunized intramuscularly with TT-loaded 
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microspheres and immune responses were evaluated at various times post-immunization. As 
determined by the induction of TT-specific serum antibody, vaccine compositions that 
contained TT-loaded CPH:SA microspheres induced a potent immune response. The 
antibody response was enhanced by the addition of a small amount (0.5 µg) of soluble TT in 
the vaccine. Antibody titer, antibody concentration half-life, antibody affinity, and 
proliferative recall responses induced by the TT-loaded microspheres were similar to or 
greater than the immune response induced by immunization with soluble TT alone. 
Furthermore, the adjuvant activity of the microspheres was demonstrated by injecting blank 
microspheres along with a sub-optimal dose (0.5 µg) of soluble TT showing an increase in 
antibody titer over 0.5µg of TT alone. Polyanhydride microspheres in quantities greater than 
0.5 mg/mouse (20 mg/kg) inhibited the development of antibody responses to co-injected TT 
alluding to a finite limit of polymer that can be incorporated into a vaccine formulation. 
Based on the evidence presented in this study, antigen-loaded microspheres prepared from 
polymers of CPH and SA are suitable for further investigation as single dose vaccine delivery 
vehicles with potential as an immunostimulatory adjuvant. 
The organization of this thesis is as follows: literature review, manuscript to be 
submitted to Vaccine containing the body of the work, general conclusion and future work to 
be done with these polymers, and two appendixes which contain some of the preliminary 
experiments from which key observations were made. The literature review has been limited 
primarily to currently licensed human vaccines, or those that are in phase III clinical trials. 
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Literature Review 
Vaccines 
The most potent and lasting immune response in a host occurs by natural infection 
with the pathogenic organism. However, for many diseases the outcome is not favorable, due 
to lack of treatment for a disease, lasting sequelae, or high mortality. Thus vaccines are used 
to mimic an infection, thereby avoiding the undesirable effects and obtaining protective 
immunity to a particular disease. A vaccine generally contains some portion of the disease-
causing agent (e.g., bacteria, virus, or toxin) in a carrier and may include an immune-
enhancer or adjuvant. Vaccines can be classified into three general categories: modified live, 
killed/inactivated, or subunit. Each has its own advantages and disadvantages. 
Other than natural infection, vaccines containing modified live organisms, relative to 
other vaccine formulations, induce the most potent and lasting immune response in the host. 
The organism is able to replicate in the host, causing a mild, limited infection that stimulates 
the host immune response in a very similar fashion to that induced by a natural infection. 
Modified live vaccines generally require the fewest number of inoculations, require no 
adjuvants, often confer lifelong immunity, and can be delivered through the same route as 
natural infection would occur [27]. For this type of vaccination regimen, the organism must 
first be attenuated, that is, the virulence capacity of the organism must be reduced. This can 
be achieved through many passages (lOOs to 1,000s) in a non-human host or in vitro or 
otherwise inducing changes (genetic manipulation) so that the organism has lost many 
virulence factors. The Sabin oral polio vaccine and Flu-mist are two examples of modified-
attenuated, live vaccines that are delivered along the same routes as the natural infection [28]. 
A closely related but non-pathogenic organism can also be used if the non-pathogen 
and pathogen share immunoprotective epitopes. For example, Jenner observed that cowpox 
infection prevented smallpox, and attenuated vaccinia virus Ankara strain was used to 
vaccinate against smallpox [ 1]. Likewise, attenuated Mycobacterium bovis BCG is protective 
against disease caused by M. tuberculosis [27]. The largest drawback to modified live 
vaccinations is that they are able to replicate in the host and thus are capable of persistent 
infection and reversion to the more virulent form. If the host is immunocompromised, the 
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organism may be able to persist, and an otherwise non-pathogenic strain may be able to 
induce disease in the absence of a competent immune system. The live organism may also be 
able to spread and induce disease in other non-vaccinated individuals. Through horizontal 
gene transfer and natural random mutation, attenuated organism may regain virulence factors 
and become able to cause disease. The attenuated strain of poliovirus used in oral vaccines 
has been shown to circulate throughout a region and occasionally revert to the disease 
causing form [28]. While modified live vaccines are very effective at inducing both cellular 
and humoral immunity, they can cause severe reactions, ranging from inflammation at the 
site of inoculation to systemic disease. Furthermore, many current diagnostic tests cannot 
distinguish between an individual who is infected and an individual that received a modified 
live vaccine [29,30]. Effectiveness oflive vaccines also requires that they be properly 
handled before administration. Keeping attenuated vaccines viable (i.e., proper storage) has 
been problematic in the worldwide effort to eradicate polio [28]. 
Killed or inactivated vaccines are comprised of the whole organism that has been 
treated with either heat or chemicals. In this way, the organism is not able to replicate in the 
host, yet, cellular integrity of the pathogen is preserved. Killed vaccines are also potent 
inducers of the humoral immune response because most of the virulence factors and epitopes 
are present [27]. However, multiple doses are often required for the induction of protective 
immunity. The degree of cellular immunity induced following immunization with killed 
vaccines can be weak. Killed vaccines do not carry the same risks as live vaccines; the 
organism cannot replicate and, therefore, cannot establish persistent infection, spread to other 
individuals, or revert to a virulent form [27]. These types of vaccines are generally cost 
effective to produce, possess a longer shelf life and are less sensitive to changes in 
temperature and handling when compared to modified live vaccines [31]. Like modified live 
vaccines, killed vaccines are highly reactogenic and are associated with a high incidence of 
side effects. Many injectable vaccines that contain killed/inactivated organisms include: polio 
virus (Salk injectable polio vaccine), whole-cell Bordetella pertussis, Hepatitis A virus, 
Yersinia pestis (causative agent of plague), and encephalitis viruses [32]. Some killed 
vaccines can be administered orally (e.g., typhoid and cholera) more closely mimicking 
natural infection [15]. 
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Subunit vaccines contain only a portion of the organism. These can be a purified 
protein or toxin, a recombinant protein, protein-polysaccharide conjugates, or DNA [32]. 
Subunit vaccines eliminate many of the side effects and reactivity associated with modified 
live or killed whole organisms. The purified protein or other subunit components can be 
prepared free ofLPS, CpG-DNA, or other phlogistic components that non-specifically 
stimulate a strong immune response. Thus, subunit vaccines are very safe, and using new 
technologies can be very cost effective to produce. Subunit vaccines are less sensitive to 
adverse storage conditions and, because many can be stored lyophilized, have long shelf 
lives. Subunit vaccines, however, have many disadvantages including poor immunogenicity 
and multiple doses are generally required for protection. To overcome the issue of poor 
immunogenicity, subunit vaccines generally require the use of an adjuvant or 
immunoenhancer (e.g., monophosphoryl lipid A). Many of the bacterial components that 
trigger a strong immune response help direct the protective response including inducing 
affinity maturation of the antibody response, increasing serum titers, and immunoglobulin 
class switching [33]. While subunit vaccines can produce a potent antibody response, the 
induction of protective cytotoxic T cell or cellular immune responses are generally lacking. 
Toxoids, inactivated bacterial toxins, were the first subunit vaccine to be employed for 
human use. Diphtheria and tetanus toxoids are formaldehyde-inactivated forms of the 
bacterial toxin that induce immune protection against the native toxin (i.e., neutralizing 
antibody). 
Components for subunit vaccines do not have to be derived from the native organism, 
they can be created utilizing recombinant technology [32]. The subunit vaccine for Lyme 
disease contained several key proteins from the bacterium produced using recombinant 
technology [32]. The polysaccharide capsule of many bacteria can be used to induce a strong 
antibody response. These carbohydrates often have to be conjugated to a protein in order to 
enhance the immunogenicity, especially when developing vaccines for infants or the elderly. 
Examples of conjugate vaccines include HiB (Haemophilus influenza type B), pneumococcal 
and meningococcal vaccines [5,32]. By injecting the DNA encoding an epitope, immunity 
can be induced against that epitope [32]. DNA can be delivered using a viral vector with the 
epitope encoded on a plasmid or DNA-containing particulates that deliver the DNA to 
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dendritic cells (DC) [34]. Host cells then express the epitope, subsequently inducing strong 
cellular immunity [35]. While many DNA vaccines are still experimental, several are 
currently in clinical trials including a DNA subunit vaccine for HIV using both a viral vector 
(adenovirus) and polymeric microparticles [36]. Also clinical trials are underway for a SARS 
subunit DNA vaccine [36]. 
Vaccine regimens generally employ an initial dose or priming dose followed by two 
to three booster doses. This prime-boost strategy allows for the presentation of high 
quantities of immunogen in the draining lymph node at several time points. The first dose 
initiates immune responses involving naive immune cells. Repeated exposure to this same 
immunogen induces activation of not only effector cells (e.g., immunoglobulin-secreting 
plasma cells) but also memory immune cells [35]. Upon subsequent exposure to the same 
immunogen, these memory cells induce a strong immune response of greater magnitude at a 
faster rate than induction of a new immune response by priming naive cells [35,37]. 
Regardless of the type of immunogen used in currently licensed vaccines (e.g. killed 
organism, subunit), the mechanism of immune-mediated protection is mediated by induction 
of neutralizing antibodies [38]. 
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Table 1.1: Current licensed vaccines, type of immunogen used, age for administration, and 
booster schedules for the United States as issued by the Department of Health and Human 
Services and The Centers For Disease Control and Prevention (CDC) as of April 2004. [5,3 
Vaccine Agent Antigen Tyne Age at First No. of Boosters 
Dose 
Tetanus Toxoid subunit 2 months 3 before 2 years, 2 at 5 
year intervals, then 1 
every 10 years 
Diphtheria subunit 2 months part ofDTaPa or Tdb 
Toxoid vaccmes 
Bordetella acellular- subunit: 2 months part of DTaPa vaccine, last 
pertussis surface antigens booster at 4-6 years 
and toxoid 
whole cell killed same as acellular not used in U.S. 
Hepatitis B subunit: <1 week 3 doses before 3 years of 
recombinant age 
Measles Attenuated 1 year 1 before entering public 
school, part ofMMRc 
vaccme 
Mumps Attenuated 1 year part ofMMRc vaccine 
Rubella Attenuated 1 year part of MMR c vaccine 
Polio Virus Killed (injectable) 2 months 2 doses before age 2, 1 
booster before entering 
public school 
Attenuated (oral) 2 months 3 doses before age 5 
Varicella Attenuated 1 year 1 at least 6 months after 
(Chicken Pox, booster in adults initial vaccination, 
Zoster) may ameliorate 
shingles 
Streptococcus polysaccharide- 2 months 3 doses before 2 years, 1 
pneumoniae protein conjugate dose before age 6 
adolescence/adult 1 dose at adulthood, 1 dose 
polysaccharide hood every 5 years for elderly 
Hepatitis A killed whole virus 2 years or older 1 dose at least 6 months 
after initial immunization 
Haemophilus polysaccharide- 2 months 3 doses before 18 months 
influenzae type B protein conjugate 
Niesseria subunit: 18 years of age none, administered as 
meningitidis polysaccharide entering college or 
military (group housing) 
Influenza Virus subunit (injectable) 6 months annually, either injectable 
attenuated (nasal) adolescence or intranasal 
aDiphtheria Toxoid, Tetanus Toxoid and acellular Pertussis antigen trivalent vaccine 
bTetanus Toxoid and Diphtheria Toxoid booster vaccine for adults 
cMeasles, Mumps and Rubella trivalent vaccine 
2] 
10 
Adjuvants 
Adjuvants are immunoenhancing materials that perform three major functions. First, 
adjuvants may provide a "depot" for the antigen, creating an antigenic reservoir for slow 
release. Second, adjuvants facilitate targeting of the antigen to immune cells, enhance 
phagocytosis, and activate antigen-presenting cells. Third, adjuvants modulate and enhance 
the type of immune response induced by the antigen alone (e.g., induce Thi vs. Th2 bias). 
Adjuvants provide the danger signal the immune system needs in order to respond to the 
antigen as it would an active infection [35]. 
The first function, providing a depot for the immunogen, is accomplished by 
entrapping the antigen in a poorly metabolized or non-dissolving substance or otherwise 
sequestering the antigen to allow for the slow clearance of the antigen from the body. Some 
of these adjuvants are discussed in more depth in other sections of the review. Aluminum 
phosphate and aluminum hydroxide, commonly referred to as alum, are the adjuvants most 
often used in human vaccines and the gel-like matrix of alum creates a slow-release 
environment for the immuogen. Adjuvants prepared as oil-in-water emulsions also slow the 
clearance of antigen from the body. For example, complete Freund's adjuvant contains killed 
mycobacteria in a mineral oil-water emulsion whereas Incomplete Freund's contains only the 
mineral oil emulsion. Incomplete Freund's adjuvant is widely used in livestock vaccines, 
even though it has a tendency to induce granulomas [39]. It is not used in humans because of 
its inherent toxicity associated with its phlogistic potential [39]. Other mineral oil emulsions, 
such as Drakeol, Marcol, ISA 206, and ISA 25 from Seppic Montanide are carriers also used 
in various livestock vaccines [39]. Recently, MF59, a variation of the biodegradable oil 
squalene, has proven to be a potent adjuvant with a satisfactory safety record and, thus, is 
suiTable for human use [39,40]. Virosomes, virus-like particles, ISCOMs, and liposomes all 
allow for the slow clearance of antigen by incorporating the antigen into small particles 
composed of lipids, phospholipids or proteins. Furthermore, antigen sequestering can be 
achieved by incorporating the antigen into microspheres composed of polymeric units of a 
biodegradable material. As the microsphere degrades, the antigen is released. Thus many 
different carrier formulations provide antigen depots once injected. 
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Adjuvants can also enhance the immune response by targeting the antigen to immune 
cells, enhancing phagocytosis, and activating the antigen-presenting cell. This can be 
accomplished by properties of the antigen, by a property of the carrier or by inclusion of 
immunostimulatory molecules. Pertussis toxin binds with high affinity to epithelial cells, 
enhancing uptake of the vaccine [35]. Other toxins, cholera toxin and Escherichia coli heat-
labile toxin, bind selectively to M cells of the intestinal tract [15]. These cells translocate the 
vaccine particle across the epithelial barrier to a region rich in lymphocytes [35,39,41]. While 
bacterial toxins such as cholera toxin and heat-labile toxin of E. coli augment a strong 
humoral (Th2) response, the response to the anti-toxin may overshadow the response to the 
conjugate antigen [35]. Another bacterial-derived immunostimulant is LPS which is derived 
from the cell wall of Gram-negative bacteria. LPS is present in vaccine preparations derived 
from whole bacteria such as B. pertussis. These bacterial products directly interact with the 
innate immune system and activated APCs through the interaction ofLPS and toll-like 
receptors (TLR) [41]. Human TLRs, when triggered by LPS, stimulate the activation ofNF-
KB, a transcriptional activator for the production of pro-inflammatory cytokines [39]. 
Because humans are very sensitive to endotoxins, LPS is generally too toxic for inclusion in 
many human vaccine preparations. Monophosphoryl lipid A (MPL or MP A) is a non-toxic 
LPS derivative obtained from Salmonella and has been shown to enhance IFN-y production 
and induction of CD4+ T cell-mediated immunity [8,15]. It is thought that MPL interacts with 
TLR 4 on APCs inducing the production oflL-12 and a Thl type immune response [8]. 
Cytokines, when included in a vaccine mixture, can enhance the immune response. In 
theory, the inclusion ofrecombinant cytokines can enhance the activation of the APC and 
also selectively direct the immune response. Delivery of IL-12 along with antigen induces 
high serum antibody titers including increased production of IgA [15]. Inclusion oflL-2 in 
intranasal vaccines shifted the immune response to TT and cholera toxin (both dominant 
Th2-type antigens) to a Thl-type immune response [15]. The antibody response to antigen 
delivered by osmotic pump was greatly enhanced by the inclusion of IL-1 ~ with the antigen 
[ 42]. The immune response to intramuscular plasmid DNA vaccination is enhanced by the 
inclusion of the gene sequence for GM-CSF [35]. Inclusion of exogenous cytokines in a 
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vaccine mixture acts directly on the APC or T cell providing the secondary signal needed to 
induce activation. 
Another consideration for the development of new adjuvants is their used for the 
induction of mucosal immunity. With few exceptions (C. tetani, rabies virus, and other insect 
vector borne pathogens), most pathogens enter the host via the mucosal surfaces (e.g., upper 
respiratory, gastrointestinal, vaginal, or urinary tracts). Induction of mucosal antibody (i.e., 
secretory IgA) by appropriate delivery of the antigen to the mucosal associated lymphoid 
tissue (MALT) is the most effective way to neutralize these pathogens or their secreted toxins 
[41]. 
Choice of adjuvant/delivery system can alter the immune response induced to the 
antigen [43]. As mentioned above, an immune response can be categorized as either Thl or 
Th2 like. Many different factors can contribute to Thl-Th2 bias of the immune response 
including route of antigen delivery (injection site, intranasal, oral), antigen dose, duration of 
antigen presentation, and inclusion of co-stimulatory molecules (e.g. LPS, exogenous 
cytokines) with the antigen [44]. Adjuvants can affect all of these factors in different ways, 
the role of the vaccinologist is the use the correct adjuvant to induce a protective immune 
response [44]. In mouse models of leishmaniasis, induction ofTh2 biased immune responses 
by vaccination does not protect the mouse from infection nor was the mouse able to clear the 
parasite illustrating that the Th 1/Th2 bias of the immune response is important in the ability 
to induce active protection [45-47]. Ova-peptide (derived from hen egg ovalbumin, OVA) 
delivered in alum did not induce a T cell response that could be stimulated in vitro [43]. 
Delivery of the same peptide within PLGA microspheres induced a significant in vitro 
proliferative response and production of IFN-y when lymphocytes were stimulated in vitro 
with OVA [43]. Cunningham et al., showed that they could alter the Thl-Th2 bias of the 
immune system to FliC flagella antigen of Salmonella by changing the antigen delivery 
system [ 48]. Antigen delivered in native state, on the surface of whole bacteria, induced 
predominantly IgG2a antibodies (Thl response) whereas recombinant soluble or polymerized 
FliC induced primarily IgGl and Th2 cytokines (IL-4) [47]. Even Freund's Complete 
Adjuvant, the gold standard of adjuvants, was ineffective for induction of protective IgG2a 
antibodies to murine Plasmodium yoelii [ 44]. Once naYve T cells have been primed and a Th 1 
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or Th2 type of immune response has been initiated, further immunizations to that antigen 
using different adjuvants cannot shift the initial immune bias [49,50]. New or novel antigens 
are not affected by this previous vaccine induced bias [ 49]. However, it is believed that 
repeated immunizations that favor a Th2 immune bias creates a situation that may lower the 
immune systems ability to initiate a new Th 1 immune response and vice versa [ 51]. Table 1.2 
summarizes the Thl/Th2 biases induced by some adjuvants. As illustrated by these examples, 
the form (e.g. particulate or soluble) of the antigen, delivery system, and route of delivery 
can all affect the Thl-Th2 bias of a subsequent immune response to a vaccine, and the type 
of immune response (Thl or Th2) that will be protective varies with the disease in question. 
Antigen, adjuvants and delivery systems need to be chosen with care to obtain the most 
protective response. Current licensed vaccines for the most part are lacking in their ability to 
induce Thl type immune responses without also generating undesirable toxic side-effects 
[12]. 
Table 1.2: Thl/Th2 bias induced in mice by administration of antigens in various adjuvants. 
[12]. t indicates relative increase and J.. indicates relative decrease in quantity of cytokine 
d d h 11 t' 1 t d. 't pro uce w en ce s were re-s 1mu a e m v1 ro. 
Adjuvant Antigen Thl/Th2 
Freund's OVA Thl 
Complete 
Lipid A (MPL) Leishmania Ag Thl 
ISCOMs OVA Thl 
HSV-2 Ag 
Alum with HIV gp120 Thl 
IL-12 
CpG Tumor Peptide Thl 
Microparticles Mucin Peptide Thl 
M. tuberculosis 
Alum* OVA Th2 
MF59* Influenza Ag Th2 
HSVAg 
* only FDA approved adjuvants for human vaccines, 
ND, not determined 
Cytokines Antibody 
Isotype 
t IFN-y, J.. IL- ND 
5 
t IFN-y ND 
t IL-12, ND 
t IFN-y IgG2a 
t IFN-y IgG2a 
t IFN-y, J.. IL- ND 
4 
t IFN-y, J.. IL- ND 
4 ND 
J.. IFN-y, t IL- IgE 
4, t IL-5 
t IL-4 t IL-, ND 
5, t IL-6 
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Alum Adjuvants 
Aluminum salts of aluminum hydroxide or aluminum phosphate, commonly referred 
to as alum, have long been used in vaccines and have an extensive safety record. Alum was 
first used as an adjuvants in 1926 [9]. Until recently, it was the only adjuvant approved for 
use in humans [9, 1 O]. Gels of aluminum phosphate for clinical use are commercially 
available and, therefore, generate consistent, predictable results [52]. Alum-based vaccines 
are prepared by suspending the antigen in a phosphate buffered solution and allowed to 
adsorb to the aluminum hydrogel [52]. The amount of antigen that adsorbs onto alum 
depends upon the electrostatic forces within the antigen, and between the antigen and the 
alum, including hydrophobic interactions, van der Waal forces, ionic charges, and hydrogen 
bonding. The typical quantity of alum in a human vaccine dose is 0.5 mg, the upper 
allowable limit by the U. S Federal Drug Administration (FDA) and World Health 
Organization (WHO) is 1.25 mg per injection [52]. Alum has proven safe for routine use in 
children, and enhances the antibody responses to protein toxoids and polysaccharide vaccines 
[52]. Alum has a synergistic effect when combined with other adjuvants and can enhance the 
adjuvant properties ofliposomes, monophosphoryl lipid A and QS-21 [52]. However, alum is 
not idea for small peptide vaccines or for use with recombinant proteins due to their inherent 
low immunogenicity [4,15,44]. 
Recently, the use of alum in vaccines has come under scrutiny. Alum has been 
occasionally associated with severe tissue reactions such as erythema, subcutaneous nodules, 
granulomas, and has been thought to induce hypersensitivity and macrophagic myofasciitis 
[10,53,54]. It is well established that alum-based vaccines induce IgE and IL-4, which are 
associated with allergy and hypersensitivity [ 1 OJ. While alum is effective at inducing str?ng 
humoral immunity, alum-based vaccines generally fail to induce cell-mediated immune 
responses such as cytotoxic T cells or delayed type hypersensitivity [12]. Alum enhances a 
strongly biased Th2 immune response in animal models [53]. Alum-based vaccines have 
other drawbacks besides the immune bias. Alum, because it is a semi-particulate hyrdogel, 
cannot be lyophilized or frozen [6], thus, limiting shelf life and storage conditions. Because 
the mode of action of alum includes the formation of antigenic deposits at the site of 
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injection, alum is not suitable for oral or intranasal immunization [15,44,55] . Finally, alum 
proved to be ineffective when used in conjunction with DNA-based vaccines [56]. 
The mechanism of adjuvanticity for alum has been traditionally thought of as 
providing a depot in the tissue for antigen. Alum-precipitated antigens are somewhat 
particulate, and, therefore more readily ingested by phagocytes [ 57]. Alhydrogel and Adju-
phos, commercially available prepared alum gels, produce particles roughly 3 to 4.5 µmin 
size [52]. Excess alum in a vaccine mixture enhances the adjuvant effect, however, alum is 
slightly cytotoxic to macrophages [52]. The evidence of the depot effect, or delayed antigen 
release, of alum adjuvants was established by White in 1967 and Harris in 193 5 by inducing 
immunity in a second animal by implanting granulomatous tissue resulting from immunizing 
the donor animal with an alum-based vaccine [52]. Recent studies with cultured macrophages 
showed that aluminum hydroxide induces a distinct maturation pattern characterized by the 
expression of surface markers that resemble those found on mature myeloid dendritic cells 
(HLA-DRhigh/CD86high/CD83+/CDla-/CD14-) and the ability activate of CD4+ T cells [53]. 
It is not known how the aluminum salts are metabolized and excreted from the body, 
if at all. For example, alum particles have been observed at the site of injection up to a year 
after immunization [52]. Macrophages recovered from muscle tissue following injection of a 
alum-based vaccine and macrophages cultured in vitro in the presence of alum, show 
persistence of crystalline inclusions [53]. 
Adjuvant Activity of Calcium Phosphate 
Calcium phosphate has been used for many years in childhood DTP vaccine 
formulations in France [10,52]. Furthermore, calcium phosphate is a normal body constituent 
and is readily absorbed [10,52]. In contrast to aluminum phosphate, calcium phosphate does 
not induce IgE production in animals or humans [10,52]. Because of this property, the most 
common use of calcium phosphate is the delivery of allergens in desensitization therapy for 
allergic patients [10,52]. In laboratory animals (e.g., mice and guinea pigs), calcium 
phosphate elicits a lower antibody response than alum-based preparations, however the 
opposite is true in humans [10]. Using calcium phosphate-based vaccine, children and 
pregnant women developed higher neutralizing antibodies than with aluminum phosphate-
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based vaccine [52]. The mode of action is thought to be the same as for alum compounds, 
functioning to create a depot for the immunogen and targeting the antigen to APCs [52]. 
Freund's Complete Adjuvant and Freund's Incomplete Adjuvant 
Freund's complete and incomplete adjuvants (CFA and IFA, respectively) are the 
standard classical adjuvants to which all other adjuvants are compared [44]. This very potent 
adjuvant system is comprised of a water-in-mineral oil emulsion with the emulsifier mannide 
monooleate [58]. Freund's complete adjuvant contains heat-killed Mycobacterium 
tuberculosis whereas IFA contains only the mineral oil emulsion and emulsifier [35,58,59]. 
Classically, protein antigens administered in CF A induce a very strong immune response, 
including cell-mediated responses, where protein antigens administered intraperitoneally in 
IFA was thought to induce tolerance [49,60]. Advances in both knowledge of the immune 
system (induction of tolerance and Th2 responses) and methodology in measuring immune 
responses have shown that administration of antigens in IF A actually induces a Th2 response. 
This response is characterized by the induction of memory T cells that home to the spleen, 
rather than the draining lymph nodes [60]. In addition, the cytokine response produced by 
these cells is small in quantity (as compared to Thl cytokines in a lymph node) and may be 
overlooked [49,61]. The presence of the mycobacterial products in CFA provide a potent 
danger signal and induces co-stimulatory signals necessary for induction ofThl-type 
cytokines. Thus, the resultant immune responses induced by CF A and IF A provide the basis 
for the differential Thl-Th2 skewing of the immune response (i.e., immune deviation) 
observed when these two similar adjuvants are employed in a vaccine [60]. Complete 
Freund's adjuvant is capable of inducing high antibody titers and long lasting T cell 
responses, but is so reactogenic that its use even in laboratory animals is discouraged [58]. 
The immune enhancing mechanisms of these adjuvants, the delayed release of antigen, 
slower antigen clearance and targeting of the antigen to APCs, is due to the mineral oil 
emulsion [35]. 
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MF59 Oil-emulsion Adjuvants 
Introduced in Europe in 1997, MF59 is an oil-in-water microemulsion that includes 
squalene (derived from a biodegradable plant oil), Polysorbate 80, and Span 85 (stabilizers) 
and small amount of muramyl tripeptide, a novel synthetic component derived from 
mycobacterial cell walls [8,59]. In clinical trials, the muramyl tripeptides proved to be still 
too toxic and are excluded from current formulations [8,40,59]. MF59 has been shown to 
stimulate a strong Th2 biased immune response to a large number of antigens and may be 
more suitable for subunit vaccines than alum [12]. MF59-based vaccines that have 
incorporated recombinant antigens induce high titer antibody responses and T cell 
proliferative responses [8]. Combination of MF59 with influenza subunits showed an 
enhanced immune response in elderly patients over that obtained using other adjuvants and is 
being evaluated for use in children [12]. MF59 does not induce Thl-type immunity (e.g., 
IFN-y) and, therefore, may not be suitable for vaccines where CMI is needed for protection 
[8]. The mechanism of adjuvanticity for MF59 appears to be in directing delivery of the 
immunogen to APCs [8]. Studies with MF59 have shown that macrophages, but not dendritic 
cells (DC), are the main cell type involved in clearing the oil depot from tissue, and DCs are 
the key antigen-presenting cells within the T cell zones of the lymph node [12]. It was 
proposed that following uptake, adjuvant-induced cell death allowed for the transfer of the 
antigen from the macrophage to the DC for T cell induction (i.e., cross-presentation) [12]. 
Another observation that arose during the development ofMF59, is the difference in 
emulsion particle size and their ability to induce immune responses in different animal 
species. Small laboratory animals (mice, guinea pigs and rabbits) develop high antibody titers 
following immunization with oil emulsion formulas regardless of particle size. However, 
non-human primates (baboons, chimpanzees) and goats require stable, small droplet 
emulsions for optimal antibody induction [ 40]. The key lesson here is that not all animal 
species respond equally to an adjuvant and testing in both large and small animals may be 
necessary to ensure activity of a novel adjuvant. 
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Monophosphoryl Lipid A 
Gram-negative bacterial extracts have strong immuno-potentating effects, however 
are too toxic for routine use in vaccines. Most of the immunostimulatory or toxic effects are 
derived from the lipid A portion of LPS, which is located in the outer-membrane of gram-
negative bacteria [58]. Further analysis showed that by removing the phosphate group, sugar 
moiety, and the ester-linked fatty acid group the toxicity could be reduced 100 to 1000 fold, 
while still retaining the immunostimulatory function [58]. Monophosphoryl lipid A (MPL), 
the resulting molecule, was derived from Salmonella minnesota [15]. Similar to LPS, MPL is 
thought to interact with TLR-4 on APCs initiating the synthesis oflL-2, IL-12, and IFN-y 
[15,39]. In animal studies, MPL induced a strong systemic Thl type immune response, 
including cytotoxic T lymphocytes (CTL) [15]. Furthermore, MPL was shown to enhance the 
production of complement fixing antibodies and increased production of secretory lgA [ 15]. 
While MPL enhanced the resulting immune response to a given antigen in comparison to the 
immune response to the soluble antigen alone, MPL is more effective when combined with 
other adjuvants or delivery systems such as QS-21 (Quil A) and polymeric microspheres, 
adjuvants that also provide a depot effect [15]. Several vaccine formulations using MPL as 
an adjuvant are in clinical trials for both humans and livestock species [39]. 
CpG Adjuvants 
Prokaryotic DNA contains unmethylated CpG dinucleotides within specific nucleic 
acid motifs that are recognized by the innate immune system of vertebrates [62]. These 
immunostimulatory motifs are the ligand for TLR-9 which is found primarily on B cells and 
DCs [62]. Signaling through binding ofTLR9 to this CpG-ligand induces the production 
reactive oxygen species and activation of NF-KB [63]. These immunostimulatory sequences 
are species specific and unique sequences have been described for laboratory animals (mice, 
rats and rabbits), humans, and non-human primates, as well as companion and farm animals 
[39]. For humans, there have been two types of CpG motifs described, type K (also known as 
B-type) and type D (or A-type) [62]. The type K CpG motifs primarily stimulate B cell and . 
monocyte proliferation, IgM, IL-10 and IL-6 secretion. Type D CpG motifs primarily 
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activate DCs, which is characterized by upregulation of CD80, CD86, MHC II, and TNF-a 
and IL-8 secretion [62]. Regardless, CpG motifs are capable of stimulating enhanced 
secretion of immunoglobulins, and may be capable of modulating pre-existing immune 
responses [33,63]. Addition of CpG to vaccine formulations has been shown to induce both 
cellular and humoral response to immunogens, inducing a Th 1 bias. CpG has been shown to 
induce demonstratable immune responses to weak immunogens such as malarial antigens, 
anti-Haemophilus influenza glycoconjugates and melanoma antigens [63]. When both alum 
and CpG motifs were included in vaccine formulations, the resulting immune response was 
Thl-biased, with no IgE production or eosinphilia [50]. Furthermore, addition of CpG motifs 
to intranasal vaccine formulations enhanced the total serum titer to influenza (viral) antigens 
in mice indicating that they may useful as immune enhancers for mucosal delivery of 
antigens [33]. 
Virosomes 
Virosomes are small lipid vesicles that contain viral fusion proteins and can be used 
to deliver vaccine antigens [56]. While theoretically a wide number of virus fusion proteins 
could be used, the majority ofvirosomes utilize the hemagglutinin (HA) and neuraminidase 
(NA) from influenza virus [56]. These particles mimic infectivity of native viruses without 
the risks associated with attenuated viruses and are capable of delivering vaccine antigens 
directly into the cytosol of the target cell [56]. This allows for induction of both humoral and 
cell mediated immunity because some of the virosome-delivered antigens have the potential 
to be presented via MHC II following endosomal processing and virosomes that escape into 
the cytosol will allow for antigenic presentation via the MHC I pathway [ 56]. Virosomes can 
be generated by either inserting fusion proteins into pre-formed small phospholipid vesicles 
(liposomes) or by separation and reconstitution of viral envelopes [56]. This type of delivery 
system has been shown to greatly enhance production of serum IgG and IgA [15]. A 
synergistic effect is observed when include other adjuvants or immunomodulators such as 
heat-liable toxin of E.coli [15]. Liposomes are effective for delivering many types of 
antigens including viral coat proteins and DNA and can be administered mucosally (e.g., 
intranasal) [15]. 
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ISCOMs 
Immunostimulating complexes (ISCOM) were first described in 1984 by Morein et 
al. [64]. These vesicles form spontaneously when phospholipids, cholesterol, and saponin-
derivative, QS21, are mixed under controlled conditions [15,64,65]. Saponin is an extract 
from the bark of Quillaja saponica trees; QS21 is a highly purified non-toxic derivative of 
saponin that contains the aliphatic portion of the molecule [15,33]. Saponins have been used 
for many years in veterinary vaccines, however, the balance of potency and adverse reactions 
must still be resolved before it is available for routine use in humans [33,58]. This adjuvant 
has been shown to induce a strong Thl immune response (CTL, IL-2, IFN-g, and IgG2a) 
because like virosomes, ISCOMs have the ability to fuse with cellular membranes and to 
deliver the immunogen into the cytosol of the target cell. This results in the endogenous 
processing and presentation of the immunogenic peptide via MHC I [15,33,64]. This 
property also makes ISCOMs good vehicles for intracellular delivery of DNA-based vaccines 
[64]. To increase antigen loading ofISCOMs, affinity tags or aliphatic regions can be 
incorporated into recombinant proteins for higher incorporation of protein into ISCOM 
membranes or chelating agents (Cu2+) can be used to increase antigen binding [58]. 
Currently, several vaccine formulations using ISCOMs with viral antigens (influenza, HIV-1, 
herpes, hepatitis B) are being evaluated in clinical trials [33]. 
Polymeric Microparticles 
Small microparticles composed of polymeric compounds are gaining in popularity as 
adjuvants and vaccine delivery vehicles because they offer both controlled single dose 
delivery and irnmunomodulatory properties. Biodegradable polymers also offer the 
advantage that MPL, CpG DNA motifs or other irnrnunoenhancing molecules can be 
incorporated to create a pathogen-mimicking solid particle [66]. Polymeric vaccine particles 
have been shown to induce demonstrable immune responses when administered by several 
routes including, parenteral (e.g. intramuscularly or subcutaneously), intranasal, or given 
orally [15]. The two most widely studied polymer classes for controlled release vaccines are 
polyanhydrides and polyesters. Other classes of polymeric compounds have been evaluated 
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and shown to successfully deliver antigen to laboratory animals. Wang et al successfully used 
microspheres made from poly-(otho-esters) for delivery of plasmid DNA to elicit a humoral 
response to ~-galactosidase and cell-mediated immune response to heat-shock protein 56 
[34]. Vaccines utilizing cross-linked dextran microparticles containing conjugated protein 
antigen (TT) induced serum antibody titers to TT [6]. Chitosan, a synthetic cationic 
polysaccharide from the exoskeleton of insects, can also be formulated into microparticles 
capable of encapsulating antigen [ 15]. Early studies with chitosan showed that the immune 
bias induced by vaccination with antigen containing chitosan microparticles was more 
dependant on the route of delivery ( e. g., intranasal vs. parenteral) than the nature of this 
adjuvant [ 15]. 
Biodegradable Biomaterials 
Biodegradable materials have been widely studied over the last two decades and are 
used in many medical applications. Biodegradable materials are used in reabsorbable sutures, 
matrixes for controlled release of therapeutic drugs, scaffolds for tissue engineering, and 
orthopedic devices (bone pins) [ 67]. Suitable biodegradable materials can exhibit different 
erosion or degradation properties depending on the type of compound used, but the 
mechanism of degradation is usually hydrolytic catalysis. Polyester compounds theoretically 
can be degraded by esterase enzymes, however, incubation of materials with esterase does 
not enhance degradation [68]. Furthermore, there is a large amount of variation in the human 
population with regards to enzyme quantities and activities, and many of these can be altered 
in diseased states. Therefore, hydrolytic catalysis of biomaterials is preferred to eliminate 
patient-to-patient variability. 
These materials also have the added advantage over stable (non-degradable) 
materials in that after placement, there is no need to remove them eliminating another 
surgical procedure. Furthermore, most are manufactured from synthetic base compounds, 
eliminating many potential reactive antigenic or allergenic epitopes that can accompany 
animal or plant derived materials. Biodegradable materials are particularly useful for 
delivering drugs to specific sites within the body. For example, 1,6-bis-(p-
carboxyphenoxypropane)-co-(sebacic acid) (CPP:SA) is marketed as a controlled delivery 
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device for chemotherapeutic agents in the treatment of glioblastoma multifome, a fatal form 
of brain cancer [69]. Patients in which the drug-containing disks are implanted in the brain 
cavity after surgical removal of the tumor do not exhibit the systemic toxicity as is seen when 
the drug is administered intravenously [69]. As of 1998, only two classes of 
implantable/injectable controlled release polymers were approved by the FDA, namely, 
poly(lactide-co-glycolide) (PLG) and polyanhydrides. 
PLA/PGA/PLGA 
Poly(lactic-glycolic acid) (PLGA) copolymers are among the few polymeric materials 
approved by the FDA for human clinical use. PLGA can be utilized for a variety of medical 
applications including reabsorbable sutures, orthopedic devices, tissue scaffolds and hormone 
and hormone antagonist delivery for prolonged periods [42,68]. The first commercial use of 
PLGA-based materials was in Vicryl, a dissolvable suture material [68]. These semi-
crystalline materials can be extruded, compressed or molded into a variety of shapes, 
including microparticles of any desired size encapsulating drugs or immunogens [68,70]. The 
greatest benefits of PLGA in biodegradable materials is that the degradation products, lactic 
acid and glycolic acid, are naturally occurring metabolites and are readily absorbed by 
neighboring cells [68,71]. Poly(lactic acid) (PLA) is naturally present in three isomeric 
forms, however, in most biomaterials the /-isomer is used [68] This is also the isomer 
preferentially metabolized by the body [68]. Poly(lactic acid) is slightly more hydrophobic 
and more crystalline in nature than poly(glycolic acid) (PGA) and therefore more resistant to 
hydrophilic attack [68]. Thus by varying the copolymer composition of PLA and PGA, 
erosion kinetics and release rates can be tailored to the desired time frame [70]. In addition, 
PLGA electrostaticly interacts with encapsulated drugs which can affect the release kinetics 
[20]. 
The general mechanism of degradation for PLGA, poly(lactic acid) (PLA) or 
poly(glycolic acid) is through hydrolysis of their ester bonds. This occurs in two stages, first 
water diffuses into the amorphous regions (PGA-rich regions) and hydrolytically cleaves 
ester groups [68]. The second stage involves ester cleavage in more crystalline microdomains 
(PLA-rich regions) [68]. Diffusion and hydrolysis is occurring throughout the material, 
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creating microtunnels and pores which further facilitate diffusion and hydrolysis [20]. This is 
referred to as bulk erosion [20]. Because of the bulk degradation, there is a considerable loss 
of mechanical stability before complete degradation has occurred [68]. For suture materials, 
this occurs at roughly 21 days postimplantation [68]. Due to the bulk eroding nature and the 
acidic degradation products, there is a considerable drop in pH both within the polymeric 
material and the surrounding microenvironment [68]. This acidity further increases the rate 
of degradation and release kinetics [20]. The resulting acidity causes localized tissue damage 
and may contribute to the inflammatory response observed as a result of injected/implanted 
PLGA materials [20]. This inflammation, however, may contribute to the adjuvant activity of 
PLGA microspheres in vaccine formulations by recruiting lymphocytic cells to the injection 
site [20]. 
Antigen-loaded PLGA microspheres function as an adjuvant by at least two 
mechanisms, first, creating a depot for the antigen in vivo, and second, directing the antigen 
in particulate form to the APCs [70]. Gupta et al observed enhanced cytokine production and 
proliferation when cells were incubated in vitro with blank PLGA microspheres indicating 
that these polymers may have other immunostimulatory properties [71]. This observation has 
yet to be further investigated. Storage limitations and sterility issues with polyesters are the 
same as for polyanhydrides [16] are discussed later in this review. 
Vaccine formulations based on PLGA, PLA or PGA variants have been successful in 
inducing immune responses to a large number of antigens including: Yersinia pestis antigens, 
HIV gp140, B. pertussis antigens, Measles virus antigen, OVA antigen, TT, Diphtheria toxin, 
malarial antigens, cancer cell antigens, E coli adhesion proteins, Vibrio cholerae antigens, 
Influenza virus antigens, Hepatitis B viral antigens and ricin toxoid [15,71]. These vaccines 
have been delivered by a variety of routes including intradermally, intravaginally, 
intranasally, orally, or parentemally into laboratory animals to induce both serum antibodies, 
mucosal IgA, cell-mediated responses and facilitated the induction of anamnenstic responses 
as determined when individuals were analyzed up to a year after primary immunization 
[71,72]. Many groups have reported a successful single dose vaccine formulation with PLGA 
microspheres of various compositions [ 18,20,23, 73-76]. Furthermore, encapsulation of 
antigens in PLGA microspheres was shown to enhance antigen presentation via MHC I 
24 
leading to increased activation of antigen specific cytotoxic T cells [17,43,73,77]. However, 
most of these studies were conducted in vitro, some investigations included MPL, a known 
Thl immune response activator in the microsphere while others used multiple injection 
regimens in vivo [17,43,73,77]. There is no consensus opinion, however, as to whether 
PLGA-based vaccines are more efficacious than current adjuvant systems. Antibody 
responses induced in mice and guinea pigs following vaccination with TT-loaded PLGA 
were greater than those induced by single injection of soluble TT or two doses of alum 
absorbed TT, additionally, a stronger anamnestic response was observed when individuals 
were boosted one year later [78]. On the other hand, Walker et al, observed that 
encapsulation of TT in PLGA microspheres did not induce serum antibody titers higher than 
alum-based TT vaccines [23]. There does not seem to be a strong correlation between release 
of antigenic peptides, length of in vitro release of peptides and immune response to those 
peptides in vivo. Only small amounts of antigenically active TT were released in the first two 
days from PLGA microspheres, even though protein continued to be released for up to 11 
weeks [78]. Denaturation of proteins and loss of antigenicity could occur during 
encapsulation when the polymer and antigens come into contact with organic solvents [78]. 
However the acidic microenvironment within the degrading PLGA microsphere has also 
shown to directly induce changes in protein stability [79-81]. Other variations in reported 
efficacy of PLGA microspheres may be due to dose of antigen, method of encapsulation (e.g. 
spray drying vs. solvent evaporation), and/or the size of the resulting microspheres [71]. 
Small microspheres (10-20 µm) generated a greater anamnestic response than larger 
microspheres (>60 µm) [78], however, nanoparticles (<600 nm) were less effective at 
inducing immune response than microspheres [77]. This may be because smaller 
microspheres (>20 µm) are more efficiently taken up by phagocytic cells than larger 
microspheres [72]. Additionally, smaller microspheres release antigen faster (release is a 
function of surface area) and in the case of TT encapsulated in PLGA, there is a marked 
decrease in antigenicity with prolonged release thus smaller microspheres release more 
immunogenic TT as a result of more rapid degradation [72]. 
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Polyanhydrides 
The structure of polyanhydrides used for controlled release materials include the 
anhydride bond in the polymer backbone that also serves as the catalytic site for chain 
breakdown [55]. This allows for the creation of a compound with a hydrophobic backbone 
and hydrolytically labile anhydride linkages. The rate of hydrolytic degradation can be 
predictably controlled by altering the composition of the polymer, which in tum, allows for 
predictable release of incorporated drugs with release rates from hours to months [25,55]. 
Inclusion of imide-groups into the polyanhydrides increases the mechanical (strength) of the 
polymer [67]. Inclusion of poly-ethylene glycol increases the hydrophilic nature of the 
polymer, which increases the rate of drug release [55]. Polyanhydrides are prepared easily 
from low cost dicarboxylic acids in a self-condensation reaction [55,82]. This eliminates the 
need for purification after synthesis or use of a reactive catalyst, many of which have 
cytotoxicity or mutagenic potential in vivo [55]. Furthermore, processing of polyanhydrides 
into a suitable material (injection molding, extrusion, emulsification, and solvent 
evaporation) occurs at low temperatures which preserve the bioactivity of any incorporated 
materials [55]. 
Protein Compatibility with Polyanhydrides: There are published reports describing 
the incorporation ofbioactive proteins into biodegradable polyanhydride devices including 
insulin, enzymes (trypsin, hen egg lysozyme, alkaline phosphatase and B-glactosidase ), and 
chondrogenic stimulating proteins [69,83]. The only reports on functionality after 
encapsulation and release were for trypsin which lost roughly 40% of its activity during 
encapsulation [83]. Following incorporation into a polymer composed of 50:50 (CPP:SA), 
the molecular size of insulin was found to be undistinguishable from non-incorporated 
insulin, and it retained biological function over the release period of 5 days [69]. More 
importantly, new microspheres could be injected into the same animal with the same level of 
effectiveness [69]. This illustrates that polyanhydrides are biologically inert as there is no 
immune response directed toward the polymer itself. Similarly, chondrogenic-stimulating 
protein remained bioactive after incorporation and release from polyanhydride microspheres 
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and was capable of stimulating growth of new limbs on chicks while blood chemistry 
parameters remained normal [69]. 
Biocompatibility of Polyanhydride Polymers: The biocompatibility of different 
polyanhydride-based polymeric compounds has been evaluated in a number of different 
tissues and animal models. Sebacic acid and carboxyphenoxypropane (CPP) was approved 
by the US Food and Drug Administration (FDA) for in vivo use in 1996 [84]. Polyanhydride 
compounds were thought to be more histocompatable than other classes of biodegradable 
compounds because they are surface eroding; thus, lower amounts of the degradation 
products are present in the local tissue area at any one time-point [84]. Poly-esters (which 
include poly-lactic acid and poly-glycolic acid) are bulk eroding compounds that degrade 
both at the surface of the particle and throughout the material at the same time (i.e., like a 
sugar cube). This leads to a higher concentration of their acidic degradation products at the 
implantation site which may result in a local inflammitory response. 
Inert materials (silicone based, some metals) when implanted evoke a typical and 
"acceptable" amount of inflammation [84]. This inflammation is characterized by cellular 
infiltration at the implantation site including large numbers of fibroblasts, few phagocytes 
(polymorphonuclear leukocytes, neutrophils, macrophages) or lymphocytes. Some formation 
of fibrotic tissue around the implant is considered a normal response to the presence of a 
foreign body [84]. Degrading biomaterials typically induce a greater amount of inflammation 
at the site of implantation than inert materials as a likely result of the continued presence of 
degradation products. Polyesters and polyanhydrides in general tend to induce an aggressive 
macrophage response. These macrophages can fuse to form the characteristic foreign body 
granulomas (e.g., giant cells, foamy macrophages) observed by some investigators 
[72,81,84,85]. One possible explanation for the increased macrophage activity is because the 
implants are releasing carboxylic acids (the degradation product of polyanhydrides) faster 
than they can be metabolized or eliminated by neighboring cells. Poly-lactic acid (PLA) has 
been shown to induce mild to moderate inflammation when implanted subcutaneously. The 
local inflammatory reactions persist for 14 to 28 days, roughly the same amount of time that 
is needed for complete degradation of PLA [72]. Polyanhydride disks composed of 25:75 
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(CPP:SA) induced a heightened inflammatory response over that observed for implanted 
PLA and the inflammation resolved as the disks degraded. However, this higher degree of 
inflammation observed with CPP:SA was deemed acceptable and compatible with new bone 
growth when evaluated for use in orthopedic materials [84]. Polyanhydrides (20:80 & 50:50 
CPP:SA) also induced more pronounced inflammation in neural tissue than SurgiGel 
(cellulose based) or GelFoam (gelatin based) [86]. Broad comparisons regarding the severity 
· of inflammation induced by polyanhydrides between investigative groups is difficult to 
assess because of the different quantities of material implanted, types of materials evaluated 
(e.g., CPP, co-imide, poly-adipic anhydride, fatty-acid dimers), evaluation of different 
histological parameters, and different criteria for scoring the severity of inflammation. For 
example, Hanes et al examined the tissue reactions to 200 mg of polyanhydride polymer that 
was implanted dorsally in rats [67]. This was estimated to be 40 to 200 times the projected 
dose that would be used in a final vaccine formulation [67]. Based on their observations, 
there was chronic inflammation characterized by the presence of high numbers of 
macrophages, few neutrophils, no edema, and no tissue necrosis. The lesion appeared to be 
progressing towards fibrosis rather than granuloma formation (defined here as acute and 
chronic inflammatory components with numerous lymphocytes and clusters of necrosis and 
cellular debris) [67]. Jiang et al examined tissue reaction tolOO mg of material manufactured 
from poly(p-carboxyphenyl succinate monoester anhydride) following tissue implantation 
[81]. They observed a large degree of macrophage infiltrate and fibrotic tissue formation. 
Further studies showed no mutagenic potential, tetragenic potential, or toxicity to liver or 
kidneys following implantation of many different polyanhydride formulations or their 
degradation products [24,81]. 
Sterilization and Storage Considerations of Polyanhydride Polymers: For a 
device to be implanted or mixture to be injected, it must be sterile or risk introducing 
infection into the host following vaccination. Each method of sterilization has potential 
drawbacks and possible negative effects due to the reactive labile bond in polyanhydrides. 
Steam sterilization temperatures are above the melting point of many anhydride compounds 
(melting point of 20:80 poly(CPH:SA) is 70°C) is and introduction of moisture induces 
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hydrolysis and pre-mature degradation of the material [25,87]. Sterilization of 
poly(trimethylene carbonate)/poly(adipic anhydride) blends was evaluated by Edlund et al, 
who found that sterilization by ~-oxidation (irradiation) or ethylene oxide gas induced 
chemical changes in the polymer blends (32). These changes including decreased 
crystallinity and hydrolysis of the polymers which can effect degradation and drug release 
kinetics [87]. Ultra-violet light (UV) irradiation of CPP:SA matrices before implantation 
yielded acceptable biocompatible results, and the polymer degraded in vivo as expected 
indicating that sterilization could be achieved with low energy UV-irradiation [24]. However, 
UV radiation may introduce free radicals into the polymer matrix that could initiate 
degradation reactions that continue during storage [87]. Higher energy y-irradiation has also 
been evaluated as a method to sterilize polyanhydrides [55]. Saturated polyanhydrides (e.g., 
poly(SA), poly(adipic acid), poly(CPH), poly(CPP) and similar mono- or co-polymers are 
stable enough to tolerate y-irradiation whereas other polyanhydrides that contain double 
bonds (e.g. based on fumaric acid, acetylenedicarboxylic acid, etc.) are unstable and y-
irradiation can generate free radicals [55]. 
Storage of polyanhydrides in air at room temperature induced changes in the surface 
structure of the polymer including hydrolysis and interchanging of anhydride-bonds [87]. 
Storage under argon in sealed glass containers preserved the integrity of the polymer over 
time (months) [87]. In fact, the need to maintain proper storage conditions is one of the few 
drawbacks associated with the use of polyanhydride polymers. For example, most 
polyanhydride polymers must be refrigerated in a moisture free environment to maintain 
polymer stability [55]. 
Control of Degradation and Drug Release from Polyanhydride Polymers: 
Microspheres based on polyanhydride compounds exhibit surface erosion ( 60). The bulk of 
the material excludes water, so only those bonds that are surface exposed are subject to 
cleavage by hydrolysis. Exclusion of water is dependant on the hydrophobic nature of 
individual monomers. For example, CPH is more hydrophobic than SA and, thus, SA:SA 
bonds are cleaved more readily than CPH:CPH bonds [88]. As the molar ratio of CPH to SA 
is increased in the polymer, the rate of hydrolytic degradation is decreased. The two 
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monomers, CPH and SA are randomly distributed within the primary structure of the co-
polymer chains. When these chains form microspheres, domains rich in CPH or SA tend to 
aggregate forming microdomains within the microspheres when the molar ratios of CPH:SA 
are vastly different (e.g., 20:80, or 80:20), but this property is not observed when the molar 
ratios are equal (e.g., 50:50) [82]. This microdomain structure complicates the rate of 
degradation because microdomains high in SA will degrade faster than microdomains of 
CPH causing a biphasic erosion front [82]. It was further shown that low molecular weight 
compounds such as acid orange or p-nitroaniline (PNA) tend to partition to the microdomain 
that is most thermodynamically favorable [89]. Solubility of the drug in aqueous solutions 
also greatly affected the partitioning within the microsphere and the release kinetics of the 
drug [89]. Acid orange, a highly soluble, hydrophilic compound, released from 20:80 
(CPH:SA) microspheres faster than could be accounted for by the overall degradation of the 
microsphere. The release of acid orange followed the same release kinetic as SA from the 
microsphere. Whereas hydrophobic, less soluble, PNA presented release kinetics that closely 
matched the release kinetics of CPH. This indicated that PNA was entrapped in the CPH 
microdomains whereas acid orange partitioned to the SA rich regions and closer to the 
surface of the individual microspheres [25]. When encapsulating proteins that are much 
larger than these two compounds, these hydrophobic/hydrophilic microdomains may not 
have as great an effect on the partitioning within the microsphere and the release kinetics. 
When microspheres loaded with FITC-BSA (fluorescein isothiocyanate labeled bovine serum 
albumin) were analyzed by fluorescent microscopy, it was observed that the distribution of 
the protein throughout the microsphere depended on the composition of the polymer. In 
poly(SA), FITC-BSA was distributed evenly throughout the microspheres, as was also the 
case with 20:80 (CPH:SA). As the CPH content increased, the protein was less evenly 
distributed throughout the microspheres [90]. In microspheres composed of 50:50 (CPH:SA) 
or 80:20 (CPH:SA), more heavily concentrated regions ofFITC-BSA were seen toward the 
outer edges of the microspheres and larger disparity was seen between protein rich and 
protein poor regions. Microspheres composed of 50:50 CPH:SA loaded with FITC-BSA did 
not exhibit the microphase separation as was observed with the low molecular weight drugs 
[89]. This indicates that the CPH interactions with larger proteins may be thermodynamically 
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unfavorable. Release kinetics ofFITC-BSA from 20:80 or 50:50 (CPH:SA) showed an initial 
burst followed by a period of zero-order release (steady-state release) [90]. The slope of the 
zero-order phase was similar to that observed in earlier reports using the low molecular 
weight drugs, being that 20:80 (CPH:SA) degraded and released the encapsulated compound 
faster than 50:50 (CPH:SA). 
Tetanus Toxoid 
Tetanus toxin (TTx) is a potent neurotropic toxin produced by Clostridium tetani, a 
gram-positive, ubiquitous, anaerobic spore-forming organism. The bacterium is found 
universally, a common inhabitant of soil, and can be found colonizing the intestinal tracts of 
animals and humans (roughly 30% of the human population) [91]. The exotoxin is encoded 
on a 74 Kbp plasmid designated pCLl [2]. Tetanus toxin is highly neurotropic, and in 
contrast to botulinum toxin, another clostridial neurotoxin, TTx has high tropism for 
presynaptic neurons of the central nervous system [92]. It binds with high affinity to the 
terminal nerve membranes, where it disrupts vesicle-membrane fusion by cleaving 
synaptobrevin and prevents acetylcholine release from the inhibitory neuron [92,93]. While 
TTx can induce polysystemic disease (blood pressure changes, respiratory dysfunction, 
hormone deregulation, kidney dysfunction, and electrolyte/fluid imbalance), TTx is most 
often associated with rigid muscular paralysis due to the disruption of inhibitory 
neurotransmitters [94,95]. This causes continuous muscle contraction often observed in 
humans in the muscles of the head, neck, and back, giving rise to the common name 
"lockjaw" [2,94,96]. A person or animal becomes infected with C. tetani when spores 
germinate and the bacterium replicates in contaminated wounds, including the umbilical cord 
stumps. Some cultural practices, such as packing the umbilical cord with animal dung, 
contribute directly to deaths caused by neonatal tetanus [94]. The replicating bacterium (i.e., 
vegetative cells) does not contribute to tissue damage in the wound, however. The exotoxin is 
second only to botulinum toxin as the most deadly substance known to man [94]. The LD50 
for mice is 0.2 ng and a lethal human (adult) dose is considered to be as little as 130 ng [91]. 
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There have been no reported cases of person-to-person transmission of TTx [97]. Infection 
with the bacterium does not always confer immunity to the toxin [97]. 
Tetanus toxin consists of two fragments, a heavy (90 kD) chain and a light (45 kD) 
chain, held together by a single disulfide bond [94,95,98]. The heavy chain is responsible for 
ataxias to the neuron by binding to the neural membrane via carbohydrate binding motif in 
the C-terminus resulting in translocation of the light chain into the neuron (Figure 1.1) 
[94,98,99]. The light chain contains the protein N-terminus, a zinc protease responsible for 
intracellular cleavage of synaptobrevin preventing docking of acetylcholine vesicles with the 
cellular membrane [94,99]. Digestion of TTx-heavy chain with papain yields two fragments, 
heavy chain B (Hb) and heavy chain C fragment (He) [ 100]. The He fragment is the 
transmembrane segment responsible for binding to the neuron and serving to anchor the 
molecule [98,101]. The Hb fragment is involved with the translocation of the light chain 
across the neural membrane [94]. The light chain alone is not able to enter the cell and induce 
disease [98]. The heavy chain alone will bind to neurons, but without the intracellular portion 
(light chain), is non-toxic [100]. 
The TTx molecule contains tightly folded secondary and tertiary structures that 
undergo considerable disruption when the light and heavy chains are disassociated, indicating 
high degree of ionic interchange between the two chains [ 101]. Furthermore, it is 
hypothesized that TTx functions as a dimer or trimer [101]. Analysis of the secondary 
structure by Fourier transform infrared spectroscopy (FTIR) shows that the protein is 
primarily composed of beta sheets (50%) with a few alpha helixes (20%) [101]. Adsorption 
to ZnSe crystals primarily induced changes in the random coil regions between the functional 
domains [101]. 
32 
Figure 1.1 Schematic diagram of tetanus toxin showing active domains within the heavy 
and light chains. Recreated from diagrams in [99,100]. 
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Circulating antibodies raised against tetanus toxoid (TT) effectively neutralize tetanus 
toxin. A toxoid is an inactivated form of the toxin, which becomes non-toxic. In the case of 
TT, TTx is treated with formaldehyde by a method first described by Ramon in 1924 [102]. 
Most of the world's TT vaccines are still produced in this way [102]. Antibody (e.g., serum 
IgG) produced against the inactivated toxoid correlates highly with protection from the native 
toxin [94,102]. While the holoprotein contains many putative Band T cell epitopes, the Hc-
fragment of the heavy chain is the most immunogenic portion of the molecule [100]. 
Immunization with just the heavy chain, more specifically just the He fragment, results in 
protection [100]. However, polyclonal multiple epitope antibodies are more efficacious than 
a single epitope monoclonal in immunoglobulin therapy [103]. Mass production methods and 
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introduction of a potent TT vaccine during WWII has made tetanus rare in developed 
countries (EU, Australia, & US) [2]. In the United States, most individuals are immunized 
with a trivalent vaccine that contains TT. Tetanus toxoid is the "T" in childhood DTaP or 
DTP vaccines, the other two components being diphtheria toxoid (D) and either acellular (aP) 
or killed whole cells of Bordetella pertussis (P), the causative agent of whooping cough. 
Immunity to TTx does wane with age in the absence of booster inoculations, and a large 
number of elderly in developed countries may lack adequate protection [2]. Given the full 
course of immunizations, in humans, TT induces a potent, lasting CD4+ memory cell 
response in humans as demonstrated by antigen specific proliferation in vitro of peripheral 
blood mononuclear cells [104,105]. 
While non-neonatal tetanus occurs worldwide, the majority of tetanus cases are 
neonatal [1]. In some areas, neonatal-tetanus can account for 25% of the infant mortality, an 
estimated 410,000 deaths, which are preventable by vaccination [ 1,2, 106]. The infant tetanus 
vaccine is effective in the presence of maternal antibodies, but several booster doses (at least 
3) are needed to establish complete protection [4,97]. The World Health Organization 
(WHO) recommends that women of childbearing age receive two consecutive doses of TT in 
order to confer protection to infants [ 106]. The current vaccination schedule for TT in the US 
is a dose of DTaP at 2, 4, 6, and 18 months of age, 6 and 16 years of age and a booster every 
10 years thereafter. Current estimation of the benefit:cost ratio for TT vaccination programs 
is 27: 1 for newborns [107]. While passive immunization with antiserum is possible, 
antiserum has to be administered at high doses shortly after injury to the susceptible 
individual, which is costly in developed countries and essentially not available in developing 
areas [ 108]. Antibody titers from passive immunization drop sharply around 4 weeks after 
administration, below a protective level, thus, leaving the individual susceptible to TTx [91]. 
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CHAPTER2: 
INDUCTION AND CHARACTERIZATION OF THE IMMUNE RESPONSE TO 
SINGLE DOSE TETANUS TOXOID VACCINE USING POLYANHYDRIDE 
POLYMER ADJUV ANTS 
A manuscript to be submitted to Vaccine, Elsevier Science Ltd., 2005. 
Jennifer H. Wilson1•2, Matt Kipper3•4, Michael Wannemuehler5•6, Balaji Narasimhan7•8 
Abstract 
The WHO has listed the development of single dose vaccines as one of the "grand 
challenges" for human health. Traditional vaccination regimes require 3 to 4 doses of an 
antigen to induce lasting immunity. This study focused on the development of a single dose 
vaccine based on biodegradable polyanhydrides. Tetanus toxoid (TT) was used as a model 
antigen. The microspheres evaluated were copolymers of sebacic acid and 1,6-bis(p-
carboxyphenoxy )hexane. By changing copolymer ratios, release kinetics of the antigen were 
modulated to obtain a sustained release, mimicking multiple doses of traditional vaccine. 
Mice (C3H/HeOuJ) were immunized once with different vaccine formulations of 
polyanhydride microspheres containing TT. Serum antibody titers to TT were evaluated over 
the course of 28 weeks. Following immunization with the TT-loaded microspheres, resultant 
antibody titers and avidity were comparable in magnitude and duration to that obtained in 
mice receiving an equivalent single dose of TT (3-10 µg). The results indicate that the 
efficacy of the immunization regimen and modulation of the immune response (i.e., Thl 
immune deviation) improved by the addition of a small amount of soluble (i.e., non-
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encapsulated) TT (0.5 µg) along with the TT-loaded microspheres. Incorporation of 0.5 µg of 
TT along with TT-loaded microspheres in the vaccine induced a shift in the antibody isotype 
as demonstrated by decreased production of IgG 1. Evidence based on antibody and recall 
proliferation responses show that polyanhydride microspheres can be used as an effective 
single dose vaccine delivery system. 
1. Introduction 
Vaccination against infectious agents has greatly improved the health of both humans 
and livestock species worldwide. Most killed and subunit vaccines require multiple doses 
within specific windows of time to create lasting, protective immunity. For example, the 
current recommendation for humans is four doses of diphtheria toxoid, tetanus toxoid (TT), 
pertussis combined vaccine given at 2, 4, 6, and 18 months of age with a booster every ten 
years [1,2]. The World Health Organization (WHO) considers a person to be adequately 
protected if they receive 3 doses of TT in some combination before 3 years of age in at least 
a 6-week interval [3,4]. Given that efficacious vaccines exist, health care workers have 
observed that as many as 70% of patients in developing countries do not return for all 
required boosters resulting in endemic disease in many parts of the world. At least two 
million children die each year from infectious diseases that are preventable through 
vaccination: measles, pertussis, and tetanus [ 5-7]. Furthermore, the costs associated with 
vaccine delivery can account for 80% of the cost of immunization programs (i.e., personnel 
to administer, refrigeration, new needles) [3]. A single dose vaccine, whether for humans or 
livestock, would greatly increase patient compliance, increase efficacy of many vaccines 
(i.e., a full dosing regime received at once), and reduce the costs associated with vaccination 
programs. The WHO listed the development of a single dose vaccine as number one in their 
"Grand Challenges" for human health. [8]. 
Only two adjuvants are currently approved for use in humans in the United States, 
alum and MF59 (a muramyl peptide variant) [9,10]. Alum is a general term for any adjuvant 
based on aluminum hydroxide, aluminum phosphate, or similar aluminum salt suspended in a 
gel-like matrix [11]. A majority of the human vaccines worldwide use alum as an adjuvant. 
One disadvantage associated with the used of alum is limited shelf life since it cannot be 
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frozen or lyophilized [I]. Alum has been associated with severe local reactions including the 
development of granulomas [12,13] and has been implicated in the rise in childhood allergies 
[ 12, 14, 15]. The increase in allergies is believed to be associated with the induction of a 
potent Th2-type response and lgE isotype antibodies following repeated immunizations with 
alum-based vaccines [ 16, 17]. Repeated biasing of the immune system towards Th2 responses 
may hinder the development ofThl-type immune responses [18]. The Th2-type immune 
response is characterized by the production ofIL-4, IL-5, IL-10, and IL-13 resulting in 
antibody class switching to lgGl and lgE isotypes [19]. Thl-type responses are characterized 
by the production ofIFN-y, TNF-~, and cell-mediated immunity including prolonged 
inflammation, activated macrophages and delayed-type hypersensitivity [20]. Cell mediated 
{Th 1) immune responses are necessary for the clearance of intracellular pathogens such as 
viruses, Mycobacterium tuberculosis and Leishmania parasites [21,22]. In some cases, such 
as Bordetella pertussis, both cell mediated {Thl) and antibodies (Th2) are required for 
complete protection [23]. Therefore, vaccine adjuvants and delivery systems must be 
developed to induce both Th 1 and Th2 immunity, or allow for selection of the most 
protective type of immune response. 
Biodegradable polymers have been studied for many years because they show 
promise for the development of single dose vaccines [24,25]. Microspheres consisting of 
polyesters have been the most widely studied [26]. Polymers of lactic acid and glycolic acid 
(e.g. poly(lactide-co-glycolide)) have proven effective in inducing lasting protective immune 
responses to a variety of antigens in laboratory animals [27]. Because polyesters are 
relatively hydrophilic, they exhibit bulk erosion. Water diffuses into the polymer creating a 
swollen matrix from which the encapsulated antigen is released by diffusion [28]. As the 
polyester degrades, an acidic microenvironment is created. Prolonged exposure to aqueous 
environments has been shown to be detrimental to the stability and immunogenicity of 
proteins, especially the proteins used in recombinant vaccines including TT and diphtheria 
toxoid [29]. 
Another widely studied class of biodegradable materials are made from random block 
polymers of anhydrides. Polyanhydrides can also be fabricated into microspheres that can 
encapsulate vaccine antigens and are currently approved by the FDA for use in a variety of 
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biomedical applications [30]. Polyanhydrides are more hydrophobic than polyesters and, 
therefore, degrade by surface erosion rather than by bulk erosion [31 ]. This hydrophobicity 
prevents water from penetrating the interior of the microsphere thus preserving the 
encapsulated antigen in its native state until that layer of the microsphere is degraded. 
Furthermore, the degradation products of polyanhydrides are less acidic which may further 
enhance the stability of encapsulated antigens and tissue compatibility [30]. Despite these 
beneficial characteristics, the use of polyanhydrides for vaccine delivery has not been 
evaluated. 
Vaccination is unique from chemotherapeutic regimen in that immune cells must be 
engaged, activated, and present the encapsulated antigen in a specific manner. Adjuvants 
have been used for decades to enhance the immune response to antigen, but their exact 
mechanisms of action are poorly understood. Effective adjuvants must enhance immune 
reactivity but at the same time avoid excessive toxicity [32]. Effective adjuvants must also 
prevent quick dispersion of the antigen and its rapid clearance from the body. This is often 
referred to as a depot effect. Freund's complete adjuvant has remained the gold standard for 
experimental adjuvants, being one of the most potent enhancers of an immune response [32]. 
The water-mineral oil emulsion prevents quick metabolism and clearance of the antigen and 
killed Mycobacterium tuberculosis enhance the innate immune response, bolstering the 
immune response to the emulsified immunogen [33]. 
It was the goal of this study to evaluate the immune response induced by antigen-
encapsulated microspheres made from copolymers of 1,6-bis(p-carboxyphenoxyhexane) 
(CPH) and sebacic acid (SA). The structures of these two compounds are shown in Figure 2-
1. The antigen used was TT, a large protein ( 150 kDa) that contains multiple immunogenic 
epitopes [7]. As evidenced by antibody responses, results indicate that vaccine compositions 
containing TT-loaded CPH:SA microspheres induced a potent immune response. This 
response was enhanced by the addition of a small amount of soluble TT. Antibody titer, 
antibody affinity, and proliferative recall responses induced by the TT-loaded microspheres 
were similar to or greater than those induced by TT alone. Furthermore, the adjuvant activity 
of the microspheres was demonstrated by injecting blank microspheres along with a non-
immunizing dose (0.5 µg) of soluble TT showing an increase in antibody titer over that dose 
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of TT alone. High doses of polyanhydride microspheres (no protein encapsulated) inhibited 
the development of antibody responses when injected in quantities greater than 0.5 
mg/mouse (20 mg/kg). 
A. 
0 
o~o 
0 
n 
B. 0 
0 
0 
m 
Figure 2-1: A. Poly-1,6-bis(p-carboxyphenoxy hexane) (CPH) and B. and 
poly(sebacic acid) (SA) where n and mare the number of repeated units. 
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2. Materials and Methods 
2.lPolymer synthesis and characterization 
Poly(CPH-SA) (20:80) and poly(CPH-SA) (50:50) were synthesized by melt 
polycondensation from acetylated prepolymers as described previously [34]. Gel permeation 
chromatography was performed on a Waters GPC system (Milford, MA) using PL Gel 
columns (Polymer Laboratories, Amherst, MA). The 20:80 copolymer had an average 
molecular weight (Mw) of 21,000 and a polydispersity index (PDI) of 2.2. The 50:50 
copolymer had an Mw of 13,000 and a PDI of 2.0. Polymers were stored desiccated under dry 
argon. 
2.2 Microsphere fabrication 
Purified TT ( 1.5 mg/ml, 490 Lf/ml) was purchased from the University of 
Massachusetts Biologic Laboratories (Jamaica Plain, MA). Protein was dialyzed against de-
ionized water for 48 hours and lyophilized before encapsulation. Microspheres encapsulating 
TT were fabricated by a water/oil/oil double emulsion method as reported elsewhere [34]. 
Polymer (100 mg) was dissolved in methylene chloride (4 ml) and TT (4 mg) was dissolved 
in nanopure water (100 µl). The TT solution was added to the dissolved polymers in a 50 ml 
centrifuge tube and immediately emulsified by agitation at 15,000 rpm with a handheld 
homogenizer (Tissue-Tearor™, Biospec Products Inc., Bartlesville, OK) for one minute. 
While still homogenizing, 4 ml of Dow Coming Fluid (silicon oil), saturated with methylene 
chloride, was added drop-wise to form the microspheres. Homogenization was continued for 
an additional minute. To precipitate the microspheres, the double emulsion was transferred to 
a 400 ml Berzelius beaker containing 300 ml n-heptane on an ice water bath. The heptane 
was stirred at 300 rpm using a Caframo overhead stirrer (Warrington, Ontario) with a three-
inch impeller for three hours to extract the methylene chloride. Heptane was periodically 
added during the solvent removal to replace the volume lost due to evaporation. The TT-
loaded microspheres were isolated by filtration using Whatman #50 filter paper. The beaker 
and impeller were rinsed several times with fresh heptane to maximize recovery. The 
microspheres were washed at least three times with 50 ml of heptane to remove residual Dow 
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Coming fluid, and dried for 24 hours under vacuum. This procedure yielded a free-flowing 
powder with about 80% of the input polymer mass being recovered. Blank microspheres 
were also fabricated by a similar technique that contained no inner water emulsion. 
2.3 Animals 
Adult mice, strain C3H/HeOuJ, at least 8 weeks of age were used for these 
experiments. Groups were arranged so that both males and females were distributed across 
all the treatment groups. Mice were obtained from the breeding colony maintained at Iowa 
State Laboratory Animal Resource Facility (Ames, IA). All animals were housed under 
specific pathogen free conditions with all bedding, caging, water and feed sterilized prior to 
use. All animal procedures were undertaken with approval from the Iowa State University 
Committee on Animal Care and Use. 
2.4 In vitro TT release kinetics 
To assess both loading efficiency and release rate of TT from the microspheres, TT-
loaded microspheres were allowed to degrade in phosphate buffered saline (PBS) (pH 7.4). 
Microspheres (3 mg) were suspended in 2 ml of 0.1 M PBS. The release buffer was sampled 
(100 µl) periodically and the volume was replaced with fresh buffer. Release experiments 
were conducted in duplicate, and preformed for every batch of TT-loaded microspheres. The 
concentration of TT in the buffer solution was assessed by micro-BCA Protein Assay (Pierce, 
Rockford, IL). 
2.5 In vivo assessment of polymer dose 
To determine what quantity of polymer would be compatible with intramuscular 
injection in mice, adult C3H/HeOuJ mice (3 per group) were injected intramuscularly (right 
quadriceps) with 3 µg TT (1 Lt) and blank (B) 20:80 poly(CPH:SA) microspheres. To 
facilitate delivery of the hydrophobic microspheres, differing amounts of blank microspheres 
were mixed with the TT solution and suspended in 50% cottonseed oil/saline emulsion. 
Cottonseed oil was thought to have no immunostimulatory effect [35]. The amounts of 
polymer injected into separate groups of mice were: 3 mg, 1 mg, and 0.5 mg. To determine if 
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the microspheres had a systemic effect on the immune response, a separate group of 3 mice 
was given 3 mg of blank microspheres in the contra lateral leg from the injection of TT. 
Following immunization, blood samples were collected weekly via the saphenous vein [36]. 
Blood was allowed to clot and serum was collected and stored at-20°C until assayed. 
Samples were collected from all three mice at each time point. 
2.6 In vivo antibody response to microsphere based vaccine formulations 
To evaluate the effectiveness of polyanhydride microspheres to induce an antibody 
response with a single injection, adult C3H/He0uJ mice (4 to 5 per group) received a single 
intramuscular (right quadriceps) injection of microspheres composed of 50:50 or 20:80 
poly(CPH:SA), suspended in sterile saline containing 0.5% fetal calf serum (FCS) as a 
surfactant. Separate groups of mice received one injection of one of the following treatments: 
1) TT-loaded microspheres (TT), 2) TT-loaded microspheres plus a 0.5 µg bolus (b) of free 
TT (TT +b ), 3) blank microspheres alone (B), 4) blank microspheres plus a 0.5 µg bolus of 
free TT (B+b ). These treatment groups were evaluated for both the 20:80 copolymer and the 
50:50 copolymer. A separate group of mice (n = 5) received only the 0.5 µg bolus of free TT 
( +b only). A final group of mice received a single dose of 5 to 10 µg TT in saline that was 
deemed an equivalent dose to that encapsulated in the microspheres. Blood samples were 
obtained and sera collected over 12 or 28 weeks as described above. 
2. 7 TT-specific enzyme-linked-immunosorbent-assay (ELISA) 
Ninety-six well microtiter plates (Costar high protein binding) were coated overnight 
with 100 µI PBS containing 1 µg/ml TT. To remove unbound TT, plates were washed with 
PBS containing 0.05% Tween 20 (PBST) and then blocked for two hours at room 
temperature with PBST containing 2% gelatin and 2% fetal calf serum (FCS). Serum 
samples ( 100 µI/well) from individual mice were serially diluted in PBST supplemented with 
2% FCS (PBST-FCS). The plates were then incubated overnight (18 h) at 4°C. The plates 
were again washed three times with PBST followed by addition of 100 µI of PBST-FCS 
containing alkaline phosphatase-conjugated goat anti-mouse IgG (H&L) (0.5 mg/ml diluted 
I :2000) (KPL, Gaithersburg, MD). After a two hour incubation period, the plates were 
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washed three times with PBST followed by the addition of 100 µl of sodium carbonate buffer 
(pH 9.3) containing phosphatase substrate (Sigma 104, Sigma-Aldrich, St. Louis, MO) at a 
concentration of 1 mg/ml and allowed to react for 1 hour at room temperature. The optical 
density (OD) of the reaction was measured at 405 nm using a Spectramax 190 Plate Reader 
(Molecular Devices, Sunnyvale CA). An ELISA to determine isotype specific responses (i.e., 
lgG2a and IgG 1 antibody) was performed similarly. Detection of isotype specific antibodies 
was accomplished using alkaline phosphatase-conjugated goat anti-mouse lgG 1 or alkaline 
phosphatase-conjugated goat anti-mouse IgG2a (Southern Biotechnology Associates, 
Birmingham, AL). Serum titers are reported as the reciprocal of the highest dilution giving an 
OD equal to or greater to a value calculated from the average of all background well in that 
days ELISA set plus two times the standard deviation of those samples. 
2.8 Measurement of antibody avidity 
The avidity of serum antibody to TT was measured using a thiocyanate elution 
immunoassay [37]. The avidity assays were preformed similarly to the ELISA described 
above, with samples and control sera set up in 8 replicates. Following the wash step and after 
the incubation with the serum samples, sodium thiocyanate was added to replicate wells in 
increasing concentrations. A range of 0 to 3M sodium thiocyanate in PBS was used. The 
mixture was incubated for 20 minutes at room temperature. Plates were then washed four 
times with PBST and detection carried out as described above. Affinity index is an estimate 
of concentration of sodium thiocyanate needed to reduce the OD obtained in the absence of 
sodium thiocyanate by 50%. 
2. 9 In vitro antigen-specific recall proliferation assay 
To evaluate the antigen-specific recall response induced by vaccination with a single 
injection of polyanhydride microspheres, immunized mice (28 weeks post immunization) 
were euthanized by C02 asphyxiation and draining lymph nodes (popliteal and inguinal) 
were removed using aseptic technique. The lymph nodes from all five mice in a group were 
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pooled. Single cell suspensions were prepared, cellular debris was removed by settling, and 
the cells were then washed via centrifugation. The cells were resuspended in culture medium 
( cRPMI) consisting of RPMI 1640 containing L-glutamine (Mediatech, Herndon, VA) and 
supplemented with 1 % nonessential amino acids (Mediatech), 1 % sodium pyruvate 
(Mediatech), 2% essential amino acids (Mediatech), 25 mM HEPES buffer (Mediatech), 100 
units/ml penicillin, 0.1 mg/ml streptomycin (Mediatech), 0.05 mg/ml gentamycin (Sigma), 
1 % L-glutamine (Mediatech), 5 x 10-5 M 2-mercaptoethanol (Sigma), and 5% heat-
inactivated FBS. Flat-bottomed 96-well microtiter plates were seeded with 5 x 105 cells in 
cRPMI at a total volume of 200 µl per well. Wells also contained either concanavalin A (Con 
A, 5 µg/ml, Sigma), differing concentrations of TT (2, 10, 25, or 50 µg/ml) or cRPMI alone 
(i.e., no stimulation). Plates were then incubated for 3 days at 37°C in 5% C02 in air. After 3 
days, 0.5 µCi of methyl- [3H]-thymidine (specific activity 6.7 Ci mmole-1, Amersham Life 
Science, Arlington Heights, IL) at a concentration of 50 µCi/ml in 10 µl of RPMI 1640 with 
L-glutamine (Mediatech) was added to each well, and the plates were incubated for an 
additional 18 hours. The contents of each well were harvested onto glass fiber filters, and the 
incorporated radioactivity was measured by liquid scintillation counting. Treatments were 
run in triplicate and data are presented as mean counts per minute (CPM) ±standard error of 
the mean (SEM) of the triplicate wells. Peripheral lymph nodes were also harvested from 
mice that received 2 doses of soluble TT (5 µg, 14 days apart). Mice were euthanized 8 
weeks following the second immunization. NaYve mice, mice receiving soluble TT and mice 
receiving 20:80TT were primed in vivo with 10 µg of soluble TT intramuscularly 5 days 
prior to euthanasia (IVP). 
2.10 Statistical analysis 
Mean titers, lgG 1/2a ratios and avidity index were calculated for each group of mice 
and analyzed for significance between groups by one-way analysis of variance (ANOV A), 
Students' t-distribution, Wilcoxon sign rank and Tukey-Kramer adjustment for construction 
of 95% confidence intervals where appropriate. P-values for statistical significance are given 
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for each case. When appropriate, data was transformed before statistical analysis following 
accepted conventions (38]. 
3. Results 
3.1 Microsphere fabrication and release kinetics 
Using scanning electron microscopy, microspheres were shown to be spherical, with 
a smooth solid surface (Figure 2-2). Particle size ranged from 5 to 30 µm. Total protein 
loading was assayed by allowing complete degradation of the microspheres in PBS and 
assaying the supernatant for protein content. As shown in Figure 2-3, the 50:50 copolymer 
did release the TT slower than the 20:80 copolymer. A sharp increase in fraction of TT 
released was observed in the first 48 hours for the 20:80 copolymer, resulting in roughly 30% 
release in the first two days. After this initial burst, the release kinetics followed zero order 
(steady state) release kinetics for the following 12 days. This sharp increase of initial release 
was not as great for the 50:50 copolymer. The 20:80 completed protein release in 12 days 
whereas the 50:50 continued to release TT for approximately 20 days. Total TT loading 
(mass%) based on cumulative protein released was 1.4% for the 20:80 copolymer and 2.0 % 
for the 50:50 copolymer. 
3.2 Polymer dosing 
The biocompatibility of polyanhydride compounds in brain, cornea, epithelia, and 
other tissues are well established (39-42]. However, vaccination differs from most 
therapeutic drug delivery, in that the immunogen and adjuvant must interact with and 
stimulate the cells of the immune system. While some inflammatory responses were 
observed in biocompatibility experiments [39,43,44], no studies have reported on the 
interaction between immune system cells and polyanhydride microspheres. Based on 
histological evaluation of muscular tissue from preliminary experiments, injection of 3 mg or 
larger quantities of polyanhydride microspheres induced chronic inflammation and muscle 
necrosis at the site of injection (data not shown, See Appendix I). In addition, mice receiving 
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quantities of TT-loaded microspheres greater than 3 mg failed to induce any antibody 
response to TT (data not shown). 
To determine the optimal immunizing dose of microspheres while minimizing 
inflammation, mice were co-injected with differing amounts of unloaded (blank, B) 
microspheres made from 20:80 copolymer (3, 1, & 0.5 mg) and 3 µg of soluble TT. The 
resulting antibody response was measured at 4 weeks post immunization (Pl) by ELISA 
(Figure 2-4 ). As the quantity of microspheres decreased, the magnitude of the antibody 
response to TT increased. When the quantity of microspheres was reduced to 0.5 mg, the 
magnitude of antibody response was not statistically different from the antibody response of 
mice that received TT alone (p<0.5). To show that the inhibition of the immune response was 
due to local factors and not systemic, mice were injected with 3 µg soluble TT in the right 
quadriceps and 3 mg of microspheres was injected in the contralateral leg (opposite). There 
was no statistical difference between the antibody response induced in mice receiving the 
contralateral injection of blank microspheres and that of mice immunized with TT alone 
(p=0.16), indicating that the inhibition of antibody response was local. From these results it 
was concluded that 0.5 mg of polymer (i.e., 20 mg/kg body weight) was the maximum 
quantity of polymer to be included in future vaccine formulations. 
3.3 In vivo antibody response to microsphere based vaccine formulations 
To determine if the polymers had immunostimulatory adjuvant properties, blank 
microspheres (no protein encapsulated) were injected with a sub-optimal dose (0.5µg) of TT. 
Mice, 5 per group, were injected in the right quadriceps with 0.5 mg of polyanhydride 
microspheres, 20:80 or 50:50 copolymer formulation, along with 0.5 µg of soluble TT. One 
group of mice each received blank 20:80 or 50:50 copolymer microspheres only. One group 
received the sub-optimal dose of soluble TT (0.5µg). The sub-optimal dose alone did not 
result in a measurable antibody response (Figure 2-5). The mice receiving the blank 
microspheres and the sub-optimal dose did demonstrate a measurable antibody titer 
significantly above sub-optimal dose alone (p~ 0.05) (Figure 2-5). These antibody titers arose 
3 to 4 weeks PI and were maintained for at least the first 12 weeks of the study (Figure 2-5). 
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To determine whether the polyanhydride microspheres could effectively deliver 
antigen and induce a demonstrable immune response following a single injection, 
microspheres were formulated to contain TT (20:80 = 2% mass fraction as TT, 50:50 = 
1.4%). Mice, 5 per group, were injected in the right quadriceps with 0.5 mg ofpolyanhydride 
microspheres, 20:80 or 50:50 copolymer formulation, containing TT (TT). One group of 
mice receiving each of the polyanhydride formulations (20:80TT, 50:50TT) also received a 
small bolus of0.5 µg of soluble TT (20:80TT+b, 50:50TT+b) along with the TT-loaded 
microspheres. At 4 weeks PI, anti-TT antibody titers from groups receiving either 20:80TT, 
20:80TT+b, 50:50TT, and 50:50TT+b were not statistically different from the group 
receiving a single dose of 10 µg of TT administered in saline (p>0.05) (Figure 2-6). At 12 
weeks PI, the groups receiving 20:80TT and 20:80TT+b had antibody titers significantly 
greater than the group receiving a single dose of soluble TT (p~ 0.05). Peak antibody titers 
were reached around 4 weeks following immunization with the 20:80 copolymer 
formulations, and 5 weeks after immunization with the 50:50 copolymer formulations 
(Figure 2-6). The small bolus of soluble TT (0.5 µg) did not enhance the magnitude of the 
overall antibody titer when injected along with the TT-loaded microspheres (Figure 2-6). 
Serum anti-TT antibody titers decreased only slightly from week 12 to 28, never more than 
two fold regardless of vaccine formulation received. 
The enhancement of anti-TT antibody responses by inclusion of polyanhydride 
microspheres in the vaccine formulations was also antigen specific. Sera was tested for 
antibodies reacting to antigens derived from Helicobacter bi/is, a resident bacterial organism 
in this mouse colony, and C5a-peptidase, a novel protein to these mice. All of the mice used 
in this study had pre-existing antibody to H. bilis antigens and no response to C5a-peptidase 
(data not shown). Following injection of the microspheres, there was no demonstrable 
increase in the anti-H. bilis or anti-C5a-peptidase antibody response in these mice. 
Tetanus toxoid has been shown to induce predominantly IgG 1 isotype antibodies 
[13,41,45-48]. Mice receiving the 20:80TT formulation induced high TT-specific IgGl with 
much less IgG2a, much like the mice receiving TT only (Figure 2-7). Mice receiving either 
the 20:80TT+b or 50:50TT+b both produced anti-TT responses with nearly equivalent titers 
of IgG 1 and IgG2a. The data shown in Figure 2-8 also indicates that the antibody response 
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was more balanced for these two groups. leading to a more balanced antibody isotype 
response as depicted in Figure 2-8. At 12 weeks, the balance of the isotypes is shifted in all 
groups due to the decline in IgG 1 antibody titers. 
3.4 Antibody avidity for TT 
There is a strong correlation between protection and the affinity of an antibody for its 
cognate antigen, regardless of antibody titer [ 49]. To determine if the microspheres affected 
the affinity of the resulting antibody response, TT-specific antibodies from mice injected 
with TT-loaded microspheres were analyzed for their relative avidity. To measure the 
relative avidity of the antibody response, sodium thiocyanate was used in increasing molar 
amounts (0.5 M to 3M) to disrupt the antibody-antigen interaction. The avidity index 
represents the molar concentration of thiocyanate needed to decrease the absorbance value to 
50% of the value obtained for untreated wells (Figure 2-9). Avidity indexes were calculated 
for serum samples collected at weeks 10 and 20 PI. There were no observable difference in 
the avidity indexes of 10 and 20-week serum samples within a given group, thus only the 10-
week data is shown in Figure 2-9. There was no statistical difference between 10 µg of 
soluble TT, any of the 20:80 copolymer formulations and 50:50TT +b (p~O. l) (data not 
shown). The resulting high avidity antibodies from 20:80B+b further indicate an adjuvant 
effect of the 20:80 copolymer and that there are inherent differences between the two 
copolymer formulations in their ability to stimulate the immune system. 
3.5 Antigen specific lymphocyte proliferation in vitro 
To determine if a memory response was generated by vaccination with polyanhydride 
microspheres, lymphocytes were recovered from microsphere immunized mice 28 weeks PI 
and from TT immunized mice 8 weeks following a second injection to measure antigen-
specific proliferation. Lymph node cells were stimulated with medium alone, ConA ( 5 µg), 
or graded doses of TT (2 to 50 µg/ml). Of all the different microsphere injection groups, only 
the 20:80TT+b group produced any measurable TT specific proliferation (only 20:80 
copolymer data shown). One group of naive mice (n = 5, age: .....,30 weeks) was immunized 
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with only the in vivo priming dose to show that 5 days was insufficient to induce TT-specific 
recall responses without previous exposure to TT. The TT-specific proliferative responses 
observed for cells recovered from these mice were not statistically different from the 
proliferative response observed for cells harvested from completely naive mice or from mice 
vaccinated once several weeks prior to euthanasia with soluble TT (p< 0.001). Counts per 
minute obtained from TT stimulated lymph node cells recovered from mice immunized with 
soluble TT plus the in vivo priming (IVP) dose and from mice immunized with 20: 80 
copolymer plus the 0.5 µg bolus of soluble TT (20:80TT+b) ranged from 10,147 to 16,650 
(Figure 2-10). These two groups were not statistically different from each other (p<0.05) 
(Figure 2-10). 
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A. B. 
Figure 2-2: Photomicrograph captured by scanning electron microscopy of protein 
loaded poly(CPH:SA) microspheres. Representative microsphere shown. A. TT-
loaded 20:80 CPH:SA, B. TT-loaded 50:50 CPH:SA 
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Figure 2-3: Kinetics of tetanus toxoid release from polyanhydride microspheres. 
Microspheres were allowed to erode in PBS at 37°C and TT (i.e., protein) concentration was 
measured in the supernatant as described in Materials and Methods. Duplicate samples were 
analyzed for each batch of microspheres. Representative sample shown. From total release, 
TT fraction (mass%) was calculated for 20:80 (2.0%) and 50:50 (1.4%). 
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Figure 2-4: Dose dependant inhibition of anti-TT antibody responses by polyanhydride 
microspheres. Serum titers of anti-TT antibodies were measured by ELISA four weeks 
following injection of different amounts of unloaded (blank) microspheres made from 20:80 
copolymer (3,1, & 0.5 mg) and 3 µg ofunencapsulated tetanus toxoid (TT). To determine if 
the inhibition shown by large doses of polymer was systemic, mice were injected with 20:80 
copolymer into the right hind leg and TT (3 µg) was injected into the left leg ( contralateral 
leg). Data presented is the mean absorbance for each group± standard error of the mean 
(SEM) at the 1 :400 dilution (n=3 ). Histograms marked with * are statically different from 
unmarked bars (P~0.05). 
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Figure 2-5: Kinetics of the serum antibody responses to sub-optimal dose of tetanus toxoid 
(TT) injected along with blank microspheres. Using an ELISA assay, as described in 
Material and Methods, the total serum IgG response to TT was evaluated over a 12-week 
period. Titer is reported as the reciprocal of the highest dilution giving an OD value greater 
than 0.100. Group mean ± standard error of the mean is shown. Mice were immunized with a 
sub-optimal dose (0.5 µg) of soluble TT ( +b) and blank (no protein loaded) 20:80 or 50:50 
copolymer (B). Naive controls received a single injection of 50 µl sterile saline. 
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Figure 2-7: Kinetics of the serum IgG 1 and IgG2a antibody isotypes in groups of mice 
receiving various formulations of tetanus toxoid (TT) loaded microspheres. Using an ELISA 
assay, as described in Material and Methods, the isotype specific IgG response to TT was 
evaluated over a 12-week period. Titer is reported as the reciprocal of the highest dilution 
giving an OD value greater that 0.100. Group mean titer± standard error of the mean is 
shown. Mice received either TT-loaded 20:80 or 50:50 copolymer (20:80TT, 50:50TT). 
Some groups in addition to the TT-loaded microspheres received a small bolus (0.5 µg) of 
soluble TT (20:80TT+b, 50:50TT+b). Control mice received a single injection of 10 µg of 
soluble TT. A.) IgGl and IgG2a serum titers from groups receiving TT-loaded 20:80 
copolymer, with and without bolus B.) lgG 1 and lgG2a serum titers from groups receiving 
TT-loaded 50:50 copolymer, with and without bolus C.) IgG I and IgG2a serum titer from the 
group receiving a single dose of soluble TT ( 10 µg) 
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Figure 2-8: Relative Th 1 vs. Th2 immune bias induced by using differing immunization 
regimes. Dashed line represents a ratio of one as a reference point (i.e., ThO or balanced 
response). Ratio of serum titers for antibody isotypes IgG 1 to IgG2a calculated for serum 
samples collected at weeks 4, 8, and 12 postimmunization. Ratios were calculated from 
group mean titers for each timepoint. Mice (n=5) received 0.5 mg of tetanus toxoid (TT)-
loaded microspheres of either 20:80 copolymer or 50:50 copolymer. Some groups received a 
small bolus of soluble TT (0.5 µg) ( +b )along with the TT-loaded microspheres. Control mice 
(n=3) received a single injection of soluble TT (10 µg) in saline. 
Figure 2-9: Measurement of the avidity of anti-tetanus toxoid (TT) antibodies induced by 
different vaccination regimens. A.) Mice received either TT-loaded 20:80 or TT-loaded 
50:50 copolymer (20:80TT & 50:50TT). Some groups in addition to the microspheres 
received a small bolus of soluble TT (0.5 µg). One group received a single dose of 0.5 µg of 
soluble TT (bolus). Control mice received a single dose of 10 µg of soluble TT (TT). The 
avidity index was calculated as described in Materials and Methods. Mean index for each 
group is shown± SEM (n =3 to 6). Histograms, in both panels, marked with a letter (a, b) are 
not significantly different from other histograms with same letter but are significantly 
different from histograms marked with different letters (p<0.05). B.) To assess the ability of 
the microspheres to act as an immunoenhancing adjuvant, mice received either blank 20:80 
or 50:50 copolymer (no protein encapsulated, 20:80B, 50:50B) (B indicates blank), in 
addition to a single dose of soluble TT (0.5 µg, bolus). 
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Figure 2-10: Antigen-specific proliferation of peripheral lymph node lymphocytes isolated 
from immunized mice. Lymph nodes were collected 28 weeks after immunization from mice 
that received tetanus toxoid (TT)-loaded 20:80 copolymer microspheres (0.5 mg) (20:80TT), 
or TT-loaded 20:80 copolymer microspheres plus 0.5 µg of soluble TT (20:80TT+b). Lymph 
nodes were also harvested from immunized with soluble TT (5 µg, 2 doses, 14 days apart) 8 
weeks after second injection. All groups designated IVP received an in vivo priming dose of 
5 µg TT administered intramuscularly 5 days prior to euthanasia. Cells were cultured in vitro 
for 72 hours and stimulated with medium alone (No Stirn), 5 µg/ml concanavalin A (ConA), 
or 10 µg/ml TT (TT 10). Data is presented as the mean counts per minute ± SEM for triplicate 
wells following incorporation of 3H-thymidine. Histogram bars marked with letters are 
significantly different from other letters but not statistically different from the same letter 
(t=0.05). 
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4. Discussion 
As the biological sciences enter the post genomic age, databases are expanded daily 
with new information relative to genomic sequences, peptide sequences, and macromolecular 
structures, and all of this is further cross-referenced by species, presumptive function, and 
shape. Utilizing this base of information, it is possible to presumptively identify antigenic 
epitopes on the surface of a pathogen based on genetic homology and protein localization 
signals, synthesize those epitopes in vitro and create a vaccine without growing the intact 
organism. This is where the bountiful harvest of information and the use of bioinformatics 
currently fails to meet our expectations. For example, bioinformatics analysis alone does not 
account for the fact that antigenic epitopes must be presented in a context that the immune 
system will recognize. In many systems it has been shown that a "danger signal" is required 
for the induction of immunological memory that will provide lasting immunity. For soluble 
recombinant peptides or carbohydrates, this had been accomplished by the addition of 
adjuvants to vaccine formulations. Many different types of adjuvants have been proposed and 
studied [ 11,21,32,50]. Most are based on immiscible lipids, inclusion of cytokines, or other 
direct immune enhancers such as bacterial components (i.e., cell wall components, LPS, un-
methylated CpG containing oglionucleotides ). Many of these components produce systemic 
effects, cause granulomas at the injection site or are otherwise too toxic to use in the general 
population [11,21,32,50]. An adjuvant classically performs two functions 1) the adjuvant 
must create a depot to reduce the rapid clearance of the antigen from the body and 2) the 
adjuvant must activate antigen presenting cells to induce the second signal necessary for 
immune activation (i.e. be immunostimulatory in some capacity). Two adjuvants used in the 
U.S. for humans accomplish these two functions by different mechanisms. Alum, aluminum 
hydroxide or aluminum phosphate suspended in a hydrogel matrix ionicly interacts with 
proteins forming small droplets (3-5 µmin diameter) that provide an immunogenic depot. 
Alum hydrogels selectively induce maturation of macrophages, inducing expression of cell 
surface MHC class II, CD86 and CD83, the ligands to the CD4 T cell receptor and co-
stimulatory receptors [ 51,52]. It is known that as the molar ratio of alum to antigen increases 
so does the adjuvanticity. At the same time, excess alum is cytotoxic to macrophages [53]. 
The second adjuvant MF59 is a water/mineral oil emulsion containing muramyl tripeptide, a 
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synthetic component similar to that found in mycobacterial cell walls [10]. This adjuvant 
establishes a depot because of the mineral oil emulsion and the synthetic bacterial component 
activates APC's by interacting with PAMP-receptors (pathogen associated molecular pattern) 
such as mannose binding proteins or toll-like receptors [54]. Both of these adjuvants induce 
a bias towards a Th2 immune response as characterized by a dominant IgG 1 antibody 
response, IgE production, weak proliferative T-cell responses, and production of IL-4. This 
tendency to induce a strong immunological bias along with limited shelf life (i.e., neither 
adjuvant can be frozen or lyophilized) limits the effectiveness of these adjuvants. Neither of 
these adjuvants enhance cytotoxic lymphocyte (CTL) responses [50,55]. For example, for 
effective clearance of pertussis or tuberculosis, both humoral (protective antibody) and CTL 
responses are necessary [ 1]. New adjuvants need to be capable of inducing both humoral and 
CTL responses, antibody of both IgG 1 and IgG2 isotypes while minimizing IgE production 
(associated with allergy and hypersensitivity) and systemic inflammation. 
Biodegradable, bioerodable materials are capable of controlled delivery of therapeutic 
drugs in vivo [56]. Mechanistic studies have shown that by altering the composition of 
biodegradable materials, the erosion and release kinetics of encapsulated drugs can be 
predictably controlled [34]. Studies using polyesters ofpoly(lactic) (PLA) and poly(glycolic) 
acid (PGA) or combinations of these two compounds (PLGA) showed that this method of 
delivery was capable of inducing measurable immune responses following a single injection 
of encapsulated immunogen that were similar to or superior to conventional alum-based 
vaccination regimes [45]. Furthermore, PLGA-based vaccines were able to induce antigen 
specific proliferative responses, elevated IFN-y production and enhanced the presentation of 
peptides in both MHC class I and class II, and enhanced the immune response to weakly 
immunogenic recombinant peptides [26]. However, it is difficult to make direct comparisons 
between most studies because of a lack of consistent methodology: dosing, exact 
composition of microspheres, methods of microsphere formation, injection route, and 
methods for analysis of the resulting response vary widely between investigative groups 
[20,29,41,45,57-60]. Furthermore, quality of materials from the different manufacturers can 
vary, which can alter the end result making evaluation of these materials between 
investigative groups difficult [26,46,61,62]. 
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One consistent drawback with the use of PLA/PGA/PLGA microspheres is related to 
the bulk eroding nature of polyesters that contributes to an aqueous environment within the 
interior of the microspheres [29]. This bulk erosion also contributes to acidification of the 
interior of the microsphere. Both acidic conditions and aqueous environments contribute to 
the destabilization of proteins. Some toxoid antigens, such as TT have been shown to loose 
antigenicity and form insoluble aggregates with prolonged exposure to aqueous environments 
[63,64]. Destabilization can induces changes in inter- and intra-bonding of peptides, causing 
aggregation of the molecules, changing the immunogenic recognition sites on the antigen or 
changes in internal bonding making peptides resistant to proteolytic degradation. The 
inability to degrade a protein may inhibit the ability to process and present the antigen in the 
context ofMHC [65]. Inclusion of gelatin or other incipient with the immunogenic proteins 
during the preparation of PLGA microspheres helps stabilize the protein and prevent some of 
these deleterious effects [29]; however, the use of gelatin in vaccines creates problems as 
well. Denatured proteins with disulfide bridges, which are present in gelatin, can induce 
strong IgE and Th2-type immune responses diminishing its usefulness relative to alum [ 65]. 
This study evaluated the use of a different class of bioerodable, biocompatible 
polymeric material. Utilizing the copolymers of sebacic acid (SA) and 1,6-bis(p-
carboxyphenoxyhexane) (CPH), we were able to demonstrate immune response to TT 
following a single administration of TT-loaded microspheres. Studies by Narasimhan et al, 
have shown that polymers based on CPH:SA are capable of controlled release of low 
molecular mass drugs and that the release could be modulated by altering the ratio of 
poly(CPH) to poly(SA) [31,66]. This was also true for the large protein, TT (Figure 2-2). 
Slower kinetics of TT release was observed from microspheres containing a higher molar 
fraction of CPH. The inhibition of the antibody response to TT when co-injected with 
amounts of polymer greater than 0.5 mg/mouse, show that the process for the incorporation 
of antigens into the microspheres must be relatively efficient (Figure 2-4). The loading 
percentage (amount of antigen per mg of polymer) must reach 2% or greater in order to 
deliver sufficient antigen since there appears to be a limiting dose of polymer. 
In vitro release kinetics may differ from the actual release rate in vivo. Langer et al 
observed a slight discrepancy between in vivo levels of drug levels released from PLGA 
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microspheres and the observed rate ofrelease from the same microspheres in vitro [58]. 
Mader et al also observed this phenomenon from poly( -fatty acid dimmer-sebacic acid) [ 67]. 
There is little experimental evidence either published [27] or from this study, that supports a 
strong correlation between in vitro rate of release from polymeric microspheres and induction 
of an antibody response as the peak serum antibody titers from both the 20:80 TT-loaded 
copolymer and the 50:50 TT-loaded copolymer occurred at the same time despite different 
release rates (Figure 2-3 and Figure 2-6). Induction of murine serum antibodies takes roughly 
10 to 14 days, the same timeframe at which TT specific antibodies were first detected in this 
study. 
Studies published by Peyre et al showed efficient phagocytosis of PLGA 
microspheres at the site of injection [68]. The migration of these particles to the peritoneal 
cavity, spleen, or draining lymph nodes could be observed for up to 2 weeks post-injection 
[ 68]. Evidence for intracellular degradation comes from Audran et al, who showed that DCs 
incubated with antigen loaded PLGA microspheres were capable of presenting that antigen in 
the context ofMHC class I for up to nine days [25]. It should be noted that these studies were 
undertaken with PLGA microspheres that exhibit very different surface properties from the 
polyanhydrides. Based on observations prior to this study, the polyanhydride microspheres 
should also have been efficiently phagocytized after injection (see Appendix I & II). 
Other than the differential ability of the polymer formulations to be phagocytized, 
there must be other factors that contributed to the lower antibody titers observed in the mice 
receiving the TT-loaded 50:50 copolymer microspheres. A possible explanation for the poor 
immune induction by 50:50TT microspheres is that the release of the antigen and 
presentation of TT in the lymph node was too low and too slow to induce sufficient T cell 
activation. The slower release kinetics of 50:50 copolymer would result in less antigen being 
available per unit of time. In addition, the loading percentage (mass fraction) of TT for the 
50:50TT was 1.4% as compared to 2% for the 20:80TT. Basically, the mice injected with 
50:50TT effectively received 7 µg of TT spread over 19 days. Data in Figure 2-6 indicates 
that there was enough peptide presented to initiate effector T cells but the prolonged 
exposure to low doses of antigen may have created poorly-functional T helper cells or 
induced a cytokine profile that effectively arrested affinity maturation of B-cells (as seen by 
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lower avidity, Figure 2-9). These observations are consistent with the inability to induce 
antigen specific proliferation of lymphocytes obtained from these mice [69]. 
The differences in the induced immune responses between the groups of mice that 
received 20:80TT, 20:80TT+b and soluble TT are more complex mechanistically than can be 
explained by the studies described herein. In addition to the antibody responses, differences 
in the host immune response to these various vaccination regimens were also differentiated 
by the fact that antigen-specific proliferation was only detected from cells recovered from the 
mice that received 20:80TT plus the soluble TT bolus. Several factors are believed to be 
important in regulating Thl vs. Th2 type immune responses including genetic background of 
the host, type of APC, the form and dose of antigen, affinity of antigen/MHC for T-cell 
receptor (TCR), route of immunization, expression of co-stimulatory molecules and 
receptors, and local environmental cytokines [22, 70]. Some of these factors are equalized 
between these three treatment groups (20:80TT, 20:80TT+b, Soluble TT). Total dose 
received was essentially the same. Mice that received soluble TT received a single injection 
of 10 µg TT in saline. Based on the in vitro release, percent loading (mass%) for 20:80TT 
was 2%, indicating that mice receiving 0.5 mg of the 20:80TT microspheres received a total 
dose of 10 µg TT that was released over 8 days and the 20:80TT+b received 10.5 µg released 
over 8 days. The same mouse strain was used for all these studies, all imniunizations were 
administered intramuscularly. Factors that may have been affected by the various regimen 
would include the type of APC that was targeted for antigen processing and presentation, and 
induction of differential cytokine profiles that may affect expression of co-stimulatory 
molecules and/or inflammatory mediators. 
It has been proposed that proteinaceous immunogens in the absence of an 
inflammatory signal does not induce a potent immune response [71]. Numerous studies have 
supported this hypothesis, thus, the emphasis on the development of adjuvants with pro-
inflammatory, yet non-toxic properties. Immunization regimens using TT appear to be 
unique in this regard. Tetanus toxoid is a large protein (150 kDa) compared to many 
immunogens (e.g. hen egg lysozyme is 14 kDa, ovalbumin is roughly 35 kDa) and has the 
tendency to aggregate ( 64 ). Thus, slight changes in the ionic strength of the buffer will 
facilitate TT to form aggregates. This may be sufficient to slow the degradation and 
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clearance of TT from the body when injected in saline, consistent with the elevated responses 
to TT observed in this study (Figure 2-4, 2-5, 2-5). Immune responses to TT may be 
enhanced by the presence of multiple epitopes, some of which are recognized specifically by 
T cells. These epitopes facilitate activation of T cells that provide immunologic help for the 
maturation and persistence of the antibody response [72]. 
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Table 2-1: Kinetics of antigen presentation in draining lymph node (LN) following 
immunization with different regimens. 
Regimen Dominant Relative Quantity of Presence of 
Antibody Release Rate TT Present Costimulatory 
Isotype From in LN at One or 
(IgG 1/IgG2a) Adjuvant Time Inflammatory 
Signals 
Soluble TTa IgGl short high spike- only 
not mechanical 
maintained damage, some 
benefit from 
aggregates 
20:80TTb IgGl medium no spike, hydrophobic 
medium and 
maintained particulate, 
mechanical 
damage 
20:80TT+b balanced medium low spike- hydrophobic, 
medium particulate 
maintained and 
mechanical 
damage 
50:50TTc balanced long low- hydrophobic 
maintained and 
particulate, 
mechanical 
damage 
50:50TT+b balanced long spike then hydrophobic, 
low particulate 
maintained and 
mechanical 
damage 
Alum ct lgGl medium high only 
particulate, 
mechanical 
damage 
a- Tetanus Toxoid, b- TT-loaded 20:80 CPH:SA copolymer microspheres, +b- with 
non-immunizing dose soluble TT, c-TT-loaded 50:50 CPH:SA copolymer microspheres, d-
information from references 24, 27 and 37. 
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Immunological dogma suggests that a single injection of an immunogen in the 
absence of an adjuvant should induce low affinity antibody. The high avidity of the anti-TT 
antibodies observed in this study following a single injection of soluble TT can be explained 
by the fact that TT contains multiple immunogenic epitopes and tends to form proteinaceous 
aggregates [73]. Thus, avidity is determined as the sum of all antibodies binding to multiple 
epitopes. Tetanus toxoid may not be the best antigen to use in single dose vaccine trials 
because mice and guinea pigs respond with high serum antibody titers to a single dose of 
soluble TT [41,48]. 
The innate immune system has many mechanisms for detecting invasion by 
pathogenic agents and detecting self from non-self. Many of these mechanisms rely on non-
specific recognition of pathogen-associated motifs (P AMPs ). Some of these receptors 
recognize molecules that are not mammalian in origin such as LPS, peptidoglycan, CpG 
motifs in DNA, and double stranded RNA [54,74]. A common feature of all of these motifs 
is that they contain hydrophobic domains and/or repeated motifs. For example, there is a high 
degree of promiscuity with many of the ligands for TLR-4 (toll-like receptor 4), and these 
ligands also all possess hydrophobic domains ( 62). This makes a strong argument that a key 
feature of P AMPs is not the prokaryotic origin of the ligand but its intrinsic hydrophobicity 
[54]. In fact, the more hydrophobic the surface of a bacterium is, the more readily it is 
phagocytosed [ 54]. There is a definite correlation between hydrophibicity and induction of 
inflammation, an issue with which biomaterial developers have long been working [ 54]. 
Inflammation is often viewed as being deleterious, except in the area of vaccine delivery. 
Hunter stated in his review of microsphere based vaccine adjuvants that the best 
adjuvant would drive the immune response without being the target of the immune system 
[32]. Polyanhydride microspheres, assessed as the whole particle, exhibit strong surface 
hydrophobicity. While this microenvironments stabilizes the antigen, surface hydrophobicity 
can also non-specifically bind serum proteins, such as complement, thus, increasing 
phagocytosis by opsonization and activating macrophages. Alternatively, the hydrophobic 
surface could induce APC activation by directly interacting with P AMPs. All of these 
mechanisms trigger co-stimulatory signals for immune induction, and yet the immune 
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response is not targeted to the anhydride itself. It is the activation of APCs that is the most 
plausible explanation for why 20:80TT+b induces less IgG 1 when compared to the antibody 
response induced by 20:80TT or soluble TT (i.e., dominant IgG 1 antibody response). 
Both polymer formulations appeared to have adjuvant activity as observed by the 
induction of a demonstrable antibody response to a sub-optimal dose of TT administered 
along with blank microspheres (Figure 2-5). This dose on its own resulted in a low antibody 
titer, with weak avidity for TT. Both the serum antibody titer and avidity were greatly 
enhanced when blank microspheres were given (Figure 2-5 & 2-8). Enhancement of serum 
antibodies to TT antigen when co-injected with blank microspheres was also observed with 
PLGA microspheres by Gupta et al [58]. This was attributed to the inflammatory response 
induced by the microspheres [58]. They also speculated that a small amount of the antigen 
could have absorbed to the surface of the microspheres (occurring in the time between 
mixing of the injection mixture and the actual injecting of the animal) allowing the soluble 
antigen to be perceived as a particulate antigen [58]. 
There is evidence of T cell involvement in the immune response to TT. Proteinaceous 
antigens are poorly processed by T cell independent pathways for the development of 
antibodies. Indirect evidence for the role of CD4 T cells in the current project can be 
extrapolated from the presence of high titer IgG (Figure 2-8), no measurable TT-specific lgM 
(data not shown), and high avidity antibody (Figure 2-9). In addition, an TT-specific 
proliferative responses were observed when lymph node cells recovered from immunized 
mice were stimulated in vitro with soluble TT (Figure 2-10). While TT is a potent generator 
of CD4 memory T cells in humans, this may not be the case for mice. Antigen specific 
proliferative cells indicative of a memory response were only observed in mice that had been 
immunized with TT-loaded polyanhydride microspheres plus a small dose of soluble TT 
(Figure 2-10). Lymph node cells recovered from mice immunized multiple times with 
soluble TT did not respond when stimulated in vitro with TT. This data supports the 
hypothesis that the polyanhydride microspheres modulate the inductive phase of an immune 
response facilitating the generation of memory T cells. 
Because of the lack of suitable vaccine adjuvant formulations, there is a need to 
develop adjuvants for use in both human and animals that provide lasting protection with a 
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single injection. There also exists a need for adjuvants that enhance Thl type immune 
responses as opposed to those that enhance Th2 immune responses. The results of this study, 
using TT as a model antigen, has shown that polyanhydride microspheres based on 20:80 
CPH:SA 1) had adjuvant (immunoenhancing) activity, 2) are potential candidates for use as 
single dose vaccine delivery system, and 3) allow for modulation in delivery that alter the 
Thl-Th2 bias of the resulting immune system. A single dose (0.5 mg) of TT-loaded 20:80 
copolymer microspheres was capable of inducing anti-TT serum antibody titers greater in 
magnitude than an equal quantity of soluble TT. Other measurements equating to the quality 
of an antibody response (longevity of response, antibody avidity) were also equal for mice 
receiving TT-loaded 20:80 copolymer microspheres and mice receiving soluble TT. Finally, 
TT-loaded 20:80 copolymer microspheres administered along with the small bolus of free TT 
induced a significant antigen-specific proliferative response that was evident 28 weeks after 
the single injection. This cell-mediated immune response was evident without further 
priming whereas immunization with soluble TT alone required an in vivo priming dose in 
order to detect the in vitro recall response. These polyanhydrides also allow for different 
delivery timing that may alter the resulting immune response. When given alone, TT induces 
a strong Th2 response, as does alum-based adjuvants. Microspheres containing TT plus the 
small bolus of soluble TT induced antigen-specific IgG 1 and lgG2a responses indicative of a 
more balanced ThO response. Taken together, this study demonstrated that sufficient antigen 
was presented in the context of TT-loaded microspheres to induce the sustained immune 
response following a single administration. In addition, this is the first study to demonstrate 
that vaccination with biodegradable, polyanhydride microspheres induce immune deviation 
to the encapsulated immunogen. 
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CHAPTER3: 
GENERAL CONCLUSIONS AND FUTURE WORK 
General Conclusions 
Most current vaccination protocols require an initial dose with 2 to 3 booster 
injections administered 2 to 6 weeks apart in order to induce protective immunity. The 
development of a single dose vaccine delivery system would enhance vaccine efficacy in 
both humans and animals by delivering the full protective dose of a vaccine at one time. It 
was the goal of this study to evaluate the potential for polyanhydride microspheres based on 
1,6-bis(p-carboxyphenoxyhexane) (CPH) and sebacic acid (SA) to serve as an effective 
delivery system for use in a single dose vaccine. 
Vaccine formulations using 20:80 (CPH:SA) copolymer microspheres in this study 
were shown to be effective delivery vehicles for a single dose vaccine. In vitro, these 
microspheres released tetanus toxoid (TT) over a 12-day period with 50% of the 
encapsulated protein being released in the first two days. As shown by the magnitude of the 
antibody response following immunization with TT-loaded microspheres in C3H/HeOuJ 
mice, this vaccine regimen was capable of inducing an antigen specific, high titer, lasting 
immune response without the need for additional booster injections. A single injection of 0.5 
mg of TT-loaded microspheres induced an anti-TT serum titer over 50,000, which was 
sustained over the 28 weeks of the study. The resultant immune response produced TT-
specific antibodies characterized by a relatively high avidity index, avidity being a relative 
measure of antibody binding affinity for it's cognate antigen. Paule et al, Pullen et al and 
Zinkemagel have shown that antibody affinity may be more important than high antibody 
titers in protecting the host from future infections [1] (Paule-2003, Pullen-1986). The 
addition of a sub-optimal dose (0.5 µg) of soluble TT did not enhance the magnitude of total 
IgG serum titers but did modulate the lgG 1-IgG2a isotype ratio. Most immunogens used in 
vaccines, including TT, and those incorporated into alum as an adjuvant, have been shown to 
induce a dominant IgG 1 antibody response (i.e., a Th2-like response). The vaccine 
formulation containing TT-loaded 20:80 copolymer microspheres and 0.5 µg of soluble TT 
84 
induced a balanced IgG l-IgG2a antibody response. In this regard, only mice vaccinated with 
a single dose of TT-loaded microspheres plus a small bolus of free TT demonstrated the 
induction of a cell-mediated immune response. Mice vaccinated with multiple doses of 
soluble TT failed to induce or presented with weak cellular responses even though high titer 
antibody responses were present. This data suggested that the polyanhydride microspheres 
could be used as a delivery device to induce long lasting protective immunity. Furthermore, 
the vaccine regimen could be rationally designed to induce a balanced immune response 
capable of eliciting both humoral and cell-mediated immunity. 
Vaccine formulations containing TT-loaded 50:50 (CPH:SA) copolymer 
microspheres did not induce as high a serum IgG titer as the TT-loaded 20:80 (CPH:SA) 
copolymer. In addition, the 50:50 copolymer formulations induced lower avidity serum 
antibody and that observation suggested that this formulation was less desirable as a vaccine 
delivery device. The release kinetics for the 50:50 copolymer were slower than the 20:80 
copolymer, releasing fully in 19 days and 50% cumulative release was not reached until 10 
days. This slower release rate along with lower loading percentage ( 1.4% TT content vs. 2% 
TT content for 20:80), may have been insufficient in releasing antigen for presentation in the 
draining lymph node in a short enough timeframe to induce a strong immune response. The 
induction of a balanced IgGl-IgG2a anti-TT antibody response following vaccination with 
TT-loaded microspheres plus soluble TT bolus was an unexpected result of these studies and, 
as stated above, the ability to modulate the immune response may prove beneficial in vaccine 
design. Because the two adjuvants currently used in human vaccines induce a dominant IgG 1 
antibody response, there is concern that these vaccine formulations may be contributing to 
the rise in allergies and asthma in developed countries (i.e., Hygiene Hypothesis). 
The 20:80 copolymer may also possess adjuvant qualities that extend beyond the 
prolonged release of antigen or depot effect. When 20:80 copolymer microspheres are 
cultured with phagocytic cells in vitro, these cells exhibit characteristics similar to stimulated 
or adjuvant activated cells [2]. When blank (no protein encapsulated) 20:80 and 50:50 
microspheres were co-injected with a small non-immunizing dose of TT (0.5 µg), a 
measurable anti-TT IgG serum titer was detected. There appears to be inherent differences 
between the 20:80 copolymer microspheres and 50:50 copolymer microspheres, which give 
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the 20:80 copolymer better adjuvant properties. The avidity of the anti-TT antibody response 
induced by the 20:80 blank microspheres with bolus was significantly higher than the avidity 
of the anti-TT antibody response induced by the 50:50 blank microspheres with bolus and not 
statistically different from higher doses of soluble TT. Furthermore, the 50:50 copolymer 
microspheres did not induce the same changes in cellular morphology in vitro as was 
observed for the 20:80 copolymer microspheres (Appendix II). Table 3-1 summarizes the 
results of this study. 
Furthermore, this study showed that there is a limit to the quantity of polyanhydride 
polymer that can be injected in vaccine formulation. For a mouse, that limit per injection was 
0.5 mg. For antigen, there will be a minimum quantity required for the induction of an 
effective immune response; for TT, this was shown to be 1 µg/mouse. Thus, for each new 
antigen destined to be included in a vaccine formulation, the quantity of immunogen required 
for the induction of an immune response must be defined in order to rationally determine the 
proper loading percentage that must be achieved within the microspheres. 
Table 3-1: Summary of immune responses following different immunization regimens 
Measurement Soluble TT 20:80TT 20:80TT+b 50:50TT 50:50TT+b 
Antibody +++ ++++ ++++ ++ ++ 
Titer 
Antibody +++ +++ +++ ++ ++ 
Avidity 
Dominant IgGl IgGl Balanced Balanced IgG2a 
Isotype lgG1/IgG2a lgG 1/lgG2a, 
titers low 
Proliferation Yes ND No ND ND 
with IVP (IVP (IVP not 
required) required) 
TT- tetanus toxoid, +b- plus small dose soluble TT (0.5 µg), IVP- In Vivo Priming: 5 µg 
soluble TT 5 days before cell harvest, ND- not preformed 
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Future Work 
The use of tetanus toxoid as a protective immunogen is well described in the literature 
and much of the single dose vaccine investigations reported to date have used TT as the 
model antigen. However, one must be cautious in making comparisons to humans because 
mice respond with high, prolonged antibody titers to TT following a single injection of TT, 
even in the absence of an adjuvant [3,4]. In addition, T cell responses to TT in C3H/HeOuJ 
mice have been difficult to evaluate. The use of other antigens, including those that induce a 
strong murine T cell response, will strengthen the evidence that polyanhydride microspheres 
are suitable single-dose vaccine delivery agents. 
The evidence of APC activation was extremely preliminary and based solely upon 
visual observations of these cells in culture. Further study of the interaction of 
polyanhydrides with these cells will allow for better evaluation of APC activation and will be 
a key component in deciding the proper polymer formulation to employ in a vaccine. This 
information would be relevant to the field of vaccinology in that increasing numbers of 
reports have shown that induction of immune responses with decided antibody biases (e.g., 
high IgG 1 vs. IgG2a) are strongly influenced by the activation status of the APC [5,6]. 
In conclusion, this study set the preliminary work in evaluating the use of 
polyanhydride polymer microspheres as a single dose vaccine delivery material. 
Polyanhydrides were shown to be effective in this regard and work will continue in order to 
further evaluate their adjuvant (i.e., APC activating) potential. 
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APPENDIX I: 
HISTOLOGICAL EVLAUATION OF TISSUES FOLLOWING INJECTION OF 
POL YANHYDRIDE MICROSPHERES 
Introduction 
Polyanhydride-based compounds are not the most widely studied biodegradable 
polymer. Some tissue compatibility studies have been preformed mostly in neural, corneal, 
and bone tissues (see Literature Review). It was concluded that compressed disks of 
polyanhydrides induced no more inflammation than other products currently in use including 
PLGA, gelatin, and cellulose-based foams [l]. Giladel is a marketed compound of 
compressed poly( carboxyphenoxy)-propane (i.e., polyanhydride) microspheres for the 
delivery of anti-tumor compounds in the treatment of malignant gilomas [2,3]. Work 
reviewed by Katti et al, leading to the approval of Giladel, stated that at 7 days post-
implantation in rat brains, edema was observed around the implant and that edema was 
resolved by day 15 [ 4]. Polymer residues were still present at the implantation site 44 days 
later. Mild inflammation was observed in muscle tissue in which disks of other 
polyanhydride compounds were implanted, and the inflammation resolved within four weeks 
[ 4]. Inflammation around the implant often included macrophages, an important cell for the 
removal of cellular debris, presentation of antigens, and induction of immune responses. 
Recruitment of these and other mononuclear antigen presenting cells to the injection site, as a 
result of the mild inflammation, could be beneficial to the induction of an immune response. 
Whereas, the formation of granulomas, development of fibrotic tissue, or other methods of 
sequestering an irritant may be detrimental to the induction of an immune response. Some 
fibrotic tissue development was observed around polyanhydride ( succinate monoesters and 
tyrosine-sebacic acid) disks implanted subcutaneously in rats but any affect on the immune 
response was not addressed [2,5]. 
A preliminary study was undertaken as part of this project to determine if 1) 
microspheres would induce granuloma-like lesions at the injection site, 2) inflammation at 
the injection site was chronic, and 3) microspheres were engulfed by phagocytes and cleared 
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from the injection site. Because the microspheres are hydrophobic, it was unclear how best to 
disperse and suspend these microspheres for accurate administration in small volumes for 
intramuscular injection (the proposed route of delivery for humans and domestic animals) in 
mice. It was concluded that an oil-based carrier with little or no immunostimulatory 
properties would work best. Mineral oil is the primary fluid component of Freund's adjuvant 
and has immunostimulatory properties on its own and, therefore, was not a suitable vehicle. 
Many seed and nut oils, such as peanut or coconut, have allergic potential and were, 
therefore, not used in these studies. Cottonseed oil has been used successfully at Iowa State 
by Dr. Hopkins in the Department of Veterinary Clinical Sciences for the delivery oflipid 
soluble hormones to cattle. The FDA assessment published on the use of cottonseed oil 
declared that it is safe and inert, having no phlogistic (inflammatory) or allergenic potential 
[6]. Cottonseed oil is the liquid component of most mascara formulations. Furthermore, 
cottonseed oil is capable of withstanding high temperature, and, thus, can be sterilized. 
Therefore, microspheres were suspended in previously sterilized cottonseed oil dry heat 
sterilized (325°C dry heat oven for 6 hours) and injected intramuscularlly into mice. 
Experiment Design 
C3H/He0uJ mice, male and female, at least 8 weeks of age, received an injection in 
the right quadriceps containing 3 mg of 50:50 CPH:SA blank microspheres suspended in 100 
µl of cottonseed oil. Two mice were sacrificed at 1, 2, 4, 8, or 11 weeks post-injection. Thigh 
muscles were excised and tissues fixed in 10% buffered formalin. Fixed tissues were 
processed and sectioned by the histopathology lab (department of Veterinary Pathology) 
using routine methods and stained with hematoxlyin and eosin (H&E). Evaluation of cellular 
infiltrate, degree of inflammation, presence of microspheres, and tissue degradation was 
preformed by Dr. Jesse Hostetter, a board certified pathologist, from the ISU Department of 
Veterinary Pathology. Two tissues were place on each slide and evaluated as a group. 
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Results and Discussion 
As the tissues were being removed, a thick yellowish exudate was observed between 
the skin and muscle or between muscle groups in all injected animals, even at 11 weeks post-
injection. However, the leg muscles did not appear swollen or abnormal and normal 
ambulation of the mouse prior to euthanasia was observed. Histological evaluation of tissue 
sections of the injected muscle revealed that microspheres (stained red) were engulfed within 
cells and that there was an area of dense macrophage (M0) and polymorphonuclear 
leukocyte (PMN) cell infiltration. Muscle cell degradation was also observed in tissue 
sections from muscles collected at 1, 2, and 4 weeks post-injection. Generalized observations 
are summarized in table A-1. Photomicrographs from tissue sections of tissues collected one 
week after injection show engulfment of the microparticle, sometimes several small 
microspheres within a single phagocyte, as shown in figure A-1.1. This is consistent with 
other reports published after this phase of the study was completed. Engulfment of multiple 
microspheres was also observed by Peyre et al. [7]. There was still a considerable amount of 
PMN and M0 infiltrate at week 2, more than would normally be expected following an 
aqueous injection (Figure A-1.2). The increased recruitment of the PMNs and M0 could be 
in response to muscular damage induced by the large amount of sebacic and carboxylic acids 
released from the degrading microspheres. Poshusta et. al., hypothesized that inflammation at 
the injection site increased slightly as the polymers began to degrade due to continual 
presence of the degradation products and that the degradation occurs faster than the body can 
clear or metabolize the degradation products [8]. At eight weeks post-injection, the 
inflammation has not completely resolved but muscle degeneration had resolved. 
Inflammatory cell infiltration was also scattered with cell debris. Numerous round particles 
are observed at the edge of the inflammatory area and between muscle groups (Figure A-1.3 
and A-1.4). They are similar to the in vivo remains of degrading CPP-SA microspheres 
described by Katti et al [4]. Observations at weeks 8 and 11 included basophilic foamy 
macrophages with large vacuoles (approximately 10 µm), which are consistent with the size 
of the microspheres, inside of lymphoid tissue (Figure A-1.5). In vitro experiments have not 
shown persistence of 50:50 microspheres over 10 weeks [9] (unpublished observations). As 
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stated above, these injections contained 3 mg of polyanhydride microspheres, a quantity that 
was later shown to be inhibitory to the induction of antibody responses. The combination of 
very viscous hydrophobic carrier (cottonseed oil) and a high dose of polymer may have 
inhibited efficient degradation of the microspheres and facilitated the formation of the 
granuloma-like tissue. 
Conclusions 
Based on this preliminary study, we were able to conclude that the microspheres were 
being engulfed at the injection site by phagocytic cells. This observation may indicate that 
antigen presenting cells not only process protein that was released from the degrading 
microspheres but may also process protein that released from phagocytized microspheres. 
Whether or not these observations imply that two separate pathways of antigen processing 
takes place remains to be determined. 
With regard to local tissue damage, histological evaluation indicated that there was a 
detrimental effect, at the injection site on muscle tissue that healed within 4 weeks. 
Degradation of the microspheres appeared to be affected depending on whether or not they 
remained free within the tissue or were taken up by phagocytic cells. At four weeks post-
injection, there appeared to be microsphere degradation occurring at the periphery of the 
inflammatory area and intact microspheres persisting within phagocytes located in the 
interior of the inflammatory area as late as 11 weeks post-injection. Cottonseed oil may have 
created a viscous, hydrophobic coating on the microspheres preventing efficient degradation 
and/or efficient clearance of the acidic degradation products. To eliminate this complication, 
cottonseed oil was not used as a carrier in subsequent studies. The accumulation of 
phagocytic cells (i.e., antigen presenting cells) at the injection site should allow for effective 
antigen processing and presentation for the subsequent induction of an antigen-specific 
immune response. Overall, the implantation of polyanhydride microspheres did not appear to 
induce a severe inflammatory response that would prohibit the use of these polymer-based 
microspheres as a vaccine delivery system. 
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Special thanks to Jim Fosse whose assistance and expertise was essential in capturing the 
digital images presented. 
Table A-1 Summarized observations of histological sections of muscle tissue recovered from 
the injection site. Mice were injected with microspheres comprised of the 50:50 copolymer 
formulation and suspended in cottonseed oil as a carrier. Inflammation and muscle 
degeneration scores were subjectively determined and scores ranged on a scale of 0 to 3. 
Slides consisted of tissues from two different animals and two slides per time point were 
evaluated in a blinded fashion by the pathologist. M0 = macrophages, PMN = 
polymorphonuclear leukocyte, PI= post injection 
Weeks PI Presence of Degree of Degree of Major Cell 
Micro spheres Inflammation Muscle Type 
Degradation 
(saline) 0 0 0 none 
1 + 2 2 M0&PMN 
2 + 2 1 M0&PMN 
4 + 2 0 M0&PMN& 
Plasma Cells 
(rare) 
8 + 1 0 M0 
11 + 2 0 M0 
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Figure A-1.1 Photomicrograph of cellular infiltrate at injection site one week post-injection. 
Section was stained with hematoxlyin and eosin, and shown at 400x magnification. 
Microspheres (stained red, *) were engulfed, sometimes several in a single phagocyte. 
f =macrophages,*= polymorphonuclear leukocytes. 
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Figure A-1.2 Photomicrograph of muscle tissue at the injection site two weeks post-injection 
with 50:50 (CPH:SA) copolymer in cottonseed oil carrier. Shown at 160x magnification, 
tissue was stained with hematoxlyin and eosin. Darker bands within the muscle fibers are 
indicative of muscle degradation (t). Some microspheres (red dots,*) can be seen within the 
cellular infiltrate. The pathologist considered the magnitude of the neutrophilic infiltrate 
unusual for two weeks post-injection (i.e., should have been fewer PMN at this time). This 
tissue section as a whole was given an inflammatory score of two and a muscle degradation 
score of I and was not considered to be severe or deleterious tissue reaction. 
95 
Figure A-1.3 Photomicrograph depicting degrading microspheres located between muscle 
groups four weeks post-injection. Shown at 160x magnification and stained with hematoxlyin 
and eosin, indicating the 50:50 (CPH:SA) microspheres were still present at the injection site 
four weeks after injection. 
Figure A-1.4 Higher magnification (400x) of same tissue section but different field from 
photomicrograph shown in Figure A-1. 3. Here the degrading micro spheres are clearer and 
the remnants of phagocytes were detected suggesting the microspheres had been previously 
phagocytized. 
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Figure A-1.5 Photomicrograph depicting muscle tissue collected from injection site 11 
weeks post-injection with 50:50 (CPH:SA) copolymer suspended in cottonseed oil carrier. 
Arrow indicates clear round vacuoles within a macrophage that may contain microspheres. 
Bar at the bottom of the figure is approximately 10 µm. Tissue section is shown at 160x 
magnification, stained with hematoxlyin and eosin. This slide was given an overall 
inflammatory score of 3. 
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APPENDIX II: 
OBSERVATIONS OF THE INTERACTIONS OF POLYANHYDRIDE 
MICROSPHERES AND CULTURED MURINE CELLS 
Introduction 
Professional antigen presenting cells (APCs) are responsible for immune surveillance, 
ingestion, and presentation of antigen to T cells and B cells along with co-stimulatory signals 
for the induction of the immune response. It had been previously reported that macrophages 
and other phagocytes readily take-up poly(lactic-co-glycoside) (PLGA) microspheres both in 
vitro and in vivo [1]. No such interactions had been shown for microspheres formulated from 
polyanhydrides. Even for PLGA, a dose effect relative to the quantity of polymer added to in 
vitro cell cultures has not been reported. However, FITC-loaded PLGA microspheres have 
been observed within adherent phagocytes [ 1]. Observations of macrophages in co-culture 
with microspheres showed that they detached from the plate when trying to engulf large 
particles. In addition, the accumulation of acidic release products from the degrading 
microspheres may have been incompatible with cells in culture. Following immunization of 
mice with polyanhydride microspheres, inhibition of antibody response was observed when 
greater than 0.5 mg of copolymer was injected (Figure 2-4). The effect of polyanhydride 
copolymer on adherent phagocytes had not yet been examined. In an attempt to show that the 
microspheres released antigenic tetanus toxoid (TT), TT-loaded microspheres were 
fabricated from poly(SA) and 20:80 (CPH:SA) copolymers were incubated with splenocytes 
collected from primed mice and proliferation measured. Poly(SA) and 20:80 copolymers 
were chosen because results with small molecular mass drugs showed in vitro release profiles 
that should be compatible with the incubation period used in these studies. Herein are the 
results of preliminary experiments designed to ascertain if sufficient TT was released in vitro 
and processed by APCs to induce lymphocyte proliferation. Unexpected results were 
observed unrelated to antigen-specific proliferation. 
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Materials and Methods 
Microsphere Fabrication 
Microspheres containing tetanus toxoid (TT) and were prepared from polymers of 
poly-sebacic acid (SA) and 1,6-bis(p-carboxyphenoxyhexane) (CPH) as described in Chapter 
2 using water/oil/water double emulsion described elsewhere [2]. Blank microspheres (i.e., 
TT) were prepared in the same manner. Analysis of loading percentages showed that each 
batch of TT loaded microspheres (both (20:80 copolymer and poly(SA)) were between 0.05 
and 0.2% loaded with TT. Microspheres loaded with FITC-BSA were prepared by Amy 
Detterman in the Narasimhan lab by similar methods described elsewhere [3]. 
Animals and Cell Cultures 
Adult mice, strain C3H/HeOuJ, at least 8 weeks of age were used for these 
experiments. Groups were arranged so that both males and females were distributed across 
all the treatment groups. Mice were obtained from the breeding colony maintained at the 
Laboratory Animal Resource Facility (Ames, IA). All animals were housed under specific 
pathogen free conditions with all bedding, caging, water, and feed sterilized prior to use. All 
animal procedures were undertaken with approval from the Iowa State University Committee 
on Animal Care and Use. Mice (n=3), C3H/HeOuJ, at least 8 weeks of age, were primed by 
two intramuscular injections of tetanus toxoid (TT) (8 µg) mixed with ImmunEasy adjuvant 
(Qiagen) 14 days apart. Naive mice (n=2), received 50 µl intramuscular injection of saline at 
the same time points. Ten days after the second immunization, mice were euthanized by C02 
asphyxiation and cells were harvested from the intraperitoneal cavity and spleen. 
Intra peritoneal cavity cells were harvested by lavage of the abdominal cavity with 
approximately 10 ml ofRPMI 1640 supplemented with 30% fetal bovine serum (FBS). The 
abdomen of each animal was gently massaged and fluid collected by withdrawing it into a 
syringe, hereafter referred to as IP cells. 
Single cell suspensions were prepared from the spleen by using the frosted end of 
sterile microscope slides. Cells were pooled for each group by type (IP or splenocytes ). 
Cellular debris was removed by settling, and the cells were then washed via centrifugation 
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and resuspended in cRPMI. Culture medium (cRPMI) consisted ofRPMI 1640 with L-
glutamine (Mediatech) supplemented with 1 % nonessential amino acids (Mediatech), 1 % 
sodium pyruvate (Mediatech), 2% essential amino acids (Mediatech), 25 mM HEPES buffer 
(Mediatech), 100 units/ml penicillin, 0.1 mg/ml streptomycin (Mediatech), 0.05 mg/ml 
gentamicin (Sigma), 1 % L-glutamine (Mediatech), 5 x 10-5 M 2-Bmercaptoethanol (Sigma), 
and 10% heat-inactivated FBS. Wells of 24 well flat-bottomed culture dishes were seeded 
with 2 x 106 cells in cRPMI at a total volume of 1 ml per well. Plates were incubated 
overnight ( 18 h) at 3 7°C in 5% C02 in air, to allow adherent cells to attach. Microspheres 
(poly(SA)-TT loaded or 20:80 copolymer TT loaded) were added the next day to selected 
wells at a concentration of 0.6 or 1.5 mg per well. As a positive stimulator of APC's, LPS 
derived from E. coli was added at a concentration of 10 µg/ml to selected wells. Plates were 
then incubated for an additional 6 days at 3 7°C in 5% C02 in air. Every 24 hours 
approximately 100 µl of fresh cRPMI containing 30% FBS was added to each well. Cultures 
were observed by light microscopy. 
Cell Staining and Visualization 
To visualize phagocytes ingesting microspheres, 0.5 ml of IP cells ( 1.5 X 106/ml) 
were obtained from TT-naive mice (n=2) as described above, were seeded into 48 well flat-
bottomed tissue culture plates. After resting for approximately 12 hours, FITC conjugated 
BSA loaded 20:80 copolymer microspheres were added (,..., 1 mg) to each well and incubated 
overnight at 37°C in 5% C02 in air. Microspheres were prepared by Amy Detterman using 
methods described elsewhere [3]. The next day, media was removed after slow speed 
centrifugation to pull cells and microspheres to the bottom of the well followed by careful 
aspiration of the medium. Cells were resuspended in F ACS buffer (PBS containing 1 % FBS 
and 0.04% sodium azide) labeled by phycoerythrin (PE) conjugated monoclonal antibodies to 
murine cell surface markers by incubation with either CD 19 (PE conjugated anti-mouse 
CD19, Pharmagen) or CDl lc (PE conjugated anti-mouse CDl lc, clone HL3, Integrimax), 5 
µl per well for one hour. Excess labeling antibody was removed by centrifugation and careful 
aspiration. F ACS fixative (200 µl) was added back to each well and cells visualized using a 
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Nixon-TE-2000U inverted microscope equipped with a Fluorescent Luminator x-cite metal 
halide bulb. 
Results and Discussion 
Within 24 hours, macrophages and other phagocytic cells adhere to the bottom of 
plastic tissue culture dishes and begin to spread, sending out characteristic dendrite-like 
appendages. In the wells with no stimulation (no microspheres or LPS), the adherent cells 
were observed to be attached but there was limited spreading of these cells (Figure A2-1A). 
When stimulated with LPS, an activator for macrophages, the spreading of these cells is more 
pronounced (Figure A2-1B). When 20:80 copolymer microspheres (with or without TT 
loaded) were added to the adherent cells, these dendrite-like cells were no longer observed 
(figure A2-1C). The microspheres did appear to float on the surface of the medium for 
several days before dispersing, but there was still a significant amount of powder still 
floating at the surface of the medium at the conclusion of the culture period. Closer 
inspection of cultures to which microspheres were added revealed the presence of dark, 
grainy, irregular objects (i.e., microspheres) (Figures A2- l C & A2-2B & C). These structures 
were absent in cultures were microspheres were not added. Another observation of these 
cultures was the increase in acidity over time, observed by the color change (from red to 
yellow) of phenol red in cRPMI, when microspheres were added to the cultures. The 
increased acidity was most likely due to the release of SA from the microspheres. 
These differences (i.e., disappearance of dendrites, rounding of cells, pH shift in the 
media) in the appearance of the cultures were observed when cells were incubated with 20:80 
or 50:50 copolymer microspheres. The splenocyte cultures incubated with 20:80 copolymer 
microspheres showed the marked disappearance of dendritic-like cells when compared to 
non-stimulated cultures (Figure A2-2). Because they are more hydrophobic than the 20:80 
microspheres, the 50:50 copolymer microspheres did not seem to induce this effect and these 
cultures resembled non-stimulated cultures (Figure A2-2). The 50:50 copolymer 
microspheres did not disperse as easily into the medium (i.e., they floated on the surface). 
The degradation rate and release of the resulting diacid monomers for 50:50 copolymer 
microspheres is also slower than for 20:80 [4]. In future experiments, it will be necessary to 
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incubate the microspheres in the medium for 12 to 24 hours prior to the addition of the cells 
to allow the microspheres to disperse within the medium. 
The disappearance of adherent cells from the bottom of the wells was an unexpected 
observation. It is possible that the adherent cells were activated and detached from the 
plastic, thus, they would be floating and not readily observed by phase contrast microscopy. 
They also could have been over-stimulated, underwent apoptosis, and effectively disappeared 
from the culture. Alternatively, the dose of polyanhydrides used in these studies was acutely 
toxic to the cells. Rounding of dendritic-like cells after several days in culture was also 
observed by Rimaniol et al., when human blood monocytes were cultured with aluminum 
hydroxide, a common adjuvant thought to induce macrophage activation [5]. When co-
cultured with aluminum hydroxide, these cells remained tightly adherent but lost the 
spreading dendrite-like morphology [5]. It is possible that SA acts as an activator of APCs or 
as with aluminum hydroxide, induces cellular differentiation causing the loss of the dendrite-
like morphology. 
To address the toxicity of microspheres to cultured cells, splenocytes were collected 
from both TT-primed and naive mice. Poly(SA) and 20:80 copolymer microspheres were 
prepared that contained TT and they were added at two different doses to cell cultures. The 
addition of microspheres (0.6 mg or 1.2 mg per ml) to culture wells did appear to affect the 
viability of the cells (Table A2- l ). At 7 days of culture, samples from select cultures were 
stained with trypan blue and counted using a hemocytometer. By increasing the 20:80 
copolymer dose to 1.2 mg per well, there was a 32% decrease in viability over wells 
receiving 0.6 mg for splenocytes from TT primed mice and 22% decrease in viability for 
splenocytes from naive mice. The decrease in viability for the poly(SA) microspheres was 
not as great, showing a decrease in viability for wells receiving 1.6 mg microspheres of 25% 
for TT primed splenocytes and 11 % for naive splenocytes. All wells receiving microspheres 
exhibited at least a 10 % decrease in viable cells as compared to wells with no treatment. An 
mechanism of toxicity was not evaluated and will need to be evaluated in future experiments. 
Results of the experiment utilizing fluorescent labeled microspheres and IP cells, 
allowed us to visualize these cells in direct interaction with the microspheres. Cell surface 
marker CD 11 c is present on myeloid cells including macrophages, monocytes, 
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polymorphonuclear leukocytes, and dendritic cells [ 6]. Furthermore, CD 11 c is up regulated 
on activated dendritic cells. Cells obtained from the peritoneal cavity generally consist of a 
high percentage of macrophages. Many of these cells stained positive with anti-CD 11 c 
antibodies when observed by fluorescent microscopy (Figure A2-3. Co-localization of FITC-
loaded microspheres and CD 11 c could be seen through out the culture for a large percentage 
of the CDl le positive cells (Figure A2-3). 
In conclusion, microspheres were being effectively phagocytized by APC's. The 
(CPH:SA) copolymer or poly(SA) microspheres were not toxic to APCs, and appeared to be 
inducing cell activation based on visual morphology. In future in vitro experiments, polymer 
quantities of less than 0.6 mg per ml will be used in order to minimize the effects on cell 
viability. Furthermore, the microspheres will be pre-incubated for 24 to 48 hours in medium 
before the addition of cells to enable the microspheres to swell and sink into the medium. 
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Table A2-1. Percent viable cells after 7 days in culture co-incubated with TT-loaded 
polyanhydride microspheres at two different concentrations. Cells were plated at 2 x 106 cells 
per ml in 24 well tissue culture plate with cRPMI. Following incubation for 7 days, cells 
were collected from each well by aspirating the wells. Cells were washed once by slow speed 
centrifugation before staining with trypan blue. Observations are based on a single 
experiment. 
Well Treatment Splenocytes from TT Splenocytes from Naive 
Primed Mice(% viable) Mice (% viable) 
20:80TT (0.6 mg/ml) 73 86 
20:80TT (1.5 mg/ml) 50 67 
poly(SA)-TT (0.6 mg/ml) 84 84 
poly(SA)-TT (1.5 mg/ml) 63 75 
TT (2 µg/ml) 96 89 
No Treatment 98 97 
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Figure A2-3: Photomicrographs of intraperitoneal exudate cells incubated for 48 hours in 
cRPMI in the presence of 1 mg per well BSA-FITC loaded 20:80 copolymer microspheres as 
visualized with fluorescent microscopy (magnification 60x). Cells were seeded at 
approximately 1.5 Xl 06 cells per ml in 24 well flat-bottomed tissue culture plate. Cells were 
stained with PE-conjugated anti-mouse CDl le antibodies. Overlay of phase contrast image 
with fluorescent images shows co-localization ofmicrospheres (green) and CDl le (red). 
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